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ABSTRACT 
 
A slow but steady increase in neurodegenerative disorders has been noted in recent 
decades. Degenerations in the nervous system are found in Alzheimer´s disease, 
Parkinson´s disease and motor neuron diseases. Amyotrophic lateral sclerosis (ALS) is 
the most common of the motor neuron diseases. It is often considered a model disorder 
of neurodegeneration. Early symptoms of ALS are limb weakness or weakness in 
muscles of speech and swallowing. Muscle atrophy follow and a slowly progressing 
paralysis spreads to respiratory muscles invariably leading to death in respiratory 
failure. Neurophysiological investigations are necessary for proper diagnosis, and it is 
important to rule out treatable diagnostic alternatives such as myopathies or 
polyneuropathies. 
 
The cause of ALS is unknown. Prevailing theories include genetic, viral, inflammatory, 
oxidative or toxic mechanisms. Some indications point toward metallotoxic etiologies. 
Clusters of ALS have been observed in regions where geological conditions cause 
elevated metal concentrations in water and soil. Several studies show increased 
frequency of ALS in certain occupations. ALS-like conditions are found in animals, 
notably in horses, where metal exposure can be suspected. In addition animal metal 
exposure experiments show accumulations of metals in the spinal cord.  
 
The aim of this thesis project is to clarify the role of metals in ALS. The hypothesis 
tested is that neurotoxic metals contribute significantly to the pathogenesis of ALS.  
To study this we have measured concentrations of 22 metals in cerebrospinal fluid 
(CSF) and plasma from patients with ALS and from controls, and correlated findings 
to literature data to suggest a model for ALS pathogenesis. 
 
Increased concentrations were found for the metals manganese, aluminum, cadmium, 
cobalt, copper, zinc, lead, vanadium and uranium in CSF from patients with ALS 
compared to controls. Manganese showed the most prominent correlation. 
Simultaneous sampling from plasma did not show these elevated concentrations, 
indicating metal accumulations in ALS CSF. Most of the metals detected in CSF 
from ALS patients are neurotoxicants.   
 
Studies of mercury distribution in a monkey showed mercury accumulations in the 
spinal cord after respiratory exposure to mercury. Motor neurons of the spinal cord 
seem to be more vulnerable to metal toxicity then surrounding cells, as they lack 
protection from the metal-binding protein metallothionein. Patient exposure to metals, 
distribution by the bloodstream, penetration of protective barriers and direct toxic 
effects on neurons of the spinal cord is suggested to be causative in ALS. 
 
It is concluded that neurotoxic metals can reach and affect the anterior horn cells of 
motor neurons and thereby contribute to the pathogenesis of ALS. 
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1 BACKGROUND 
 
“There is a species of paralysis frequently attacking the superior extremities….Of the 
actual cause of this affection, as of the proper means of treatment, I can, I fear, add 
little…” 
 
This description is written in 1831 by the physician at the Birmingham Dispensary Dr 
John Darwall (Darwall 1831). He describes a paralysis of unknown cause and he can 
offer no treatment. Later in the 19
th
 century the French neurologist Aran describes a 
small case series of 11 patients with a previously not appreciated malfunction of the 
motor system in whom he notes a strange feature of this weakness: “instead of affecting 
the whole limb or part of a limb, as seen in other atrophies, it irregularly affects certain 
muscles, while it spares others” (Aran 1850). It is instructive to note that 3 out of 11 
cases in the original presentation by Aran had been exposed to lead (Pb) and 2 of them 
actually had a history of Pb intoxication (Aran 1850).  
 
In 1862 Clarke presented what was maybe the first histopathological description of 
spinal cord correlates to this kind of weakness in a former US military surgeon: “All 
the white columns of the cord in every region, but particularly in the cervical region,  
suffered more or less from atrophy or degeneration…the anterior roots of the nerves 
were decidedly below their average size” (Radcliffe 1862). An original drawing of 
these atrophic spinal cord cells can be seen in Figure 1. 
 
In 1865 Charcot demonstrated to the audience at Société Médicale des Hôpitaux de 
Paris a woman, previously diagnosed as hysteric palsy, with progressive weaknesses, 
where he at autopsy could identify lateral column degeneration and sclerosis in the 
spinal cord. In other cases he demonstrated lesions in the brain stem connected to 
weakness of the muscles of the face, mouth, and tongue. Charcot noted pathological 
changes in both the pyramidal tracts from the brain and in the anterior spinal nerve 
roots and the definite term ALS defining this clinico-pathological entity, was used for 
the first time (Charcot 1874).  
   
But maybe these pioneering neurologists were describing a weakness actually present 
in humans for a very long time. The word palsy dates back to 1582 and early scattered 
cases described as wasting palsy, lead paralysis without lead, or creeping paralysis can 
be found in older literature. From ancient Rome cases of generalized muscle weakness 
and wasting are known and even the Bible describes muscle wasting and weakness. We 
are dealing with an old problem.     
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 NEURODEGENERATIVE DISORDERS 
Motor neuron disease (MND) is a disorder of the nervous system characterized by 
atrophy of skeletal muscle and sclerosis of motor pathways in the spinal cord. It is 
one out of several neurodegenerative disorders such as Alzheimer’s dementia and 
Parkinson’s disease and other conditions where degeneration of nerve cells is the 
common denominator. Some overlap exist between these degenerative states and the 
search for common pathophysiological mechanisms has been intensified (Greenfield 
and Vaux 2002, Hamilton and Bowser 2004) in recent years. These disorders show 
onset in advanced age and a slow but steady progression of disease. The causes of 
these disorders are largely unknown. The most common MND is amyotrophic lateral 
sclerosis (ALS). It is often considered a model disorder for neurodegeneration and it 
is chosen for study in this thesis.  
 
1.2 ANATOMY 
ALS is a disorder of the corticospinal tracts and the brain (Figure 2). From the motor 
cortex nerve action potentials travel through upper motor neurons to anterior horn cells 
of the spinal cord. From these cells the signals follow lower motor neurons from the 
spinal cord to muscles where they pass the motor endplates to muscle cells where they 
cause muscle contraction and muscle growth. At autopsy of ALS cases anterior and 
lateral columns of the spinal cord are found stiff and hard i.e. sclerotic. Degeneration of 
these motor neurons leads to progressive muscle weakness and atrophy of skeletal 
muscles. Atrophic muscles in ALS are most often seen in the small hand muscles 
Figure 1. Anterior horn cells of the spinal cord. Original drawing showing 
(a) “atrophied cells from the cervical enlargement magnified 420 diameters”, together with 
(b-d) “healthy cells from the same quarter, and magnified to the same extent”. From 
(Radcliffe 1862). 
 3 
 
corresponding to anterior horn cells at low cervical levels. Symptoms from the brain 
stem involving cranial nerve motor nuclei are noted first in some 20% of ALS and 
these cases often present with speech problems. ALS is a disorder within the nervous 
system where the conduction between cortex and muscles has degenerated leaving the 
lateral columns sclerotic and where the muscles become atrophic. Widespread 
irreversible muscle atrophy is seen in ALS.       
 
 
Figure 2. Corticospinal tract (blue) conveying motor signals from motor cortex to skeletal 
muscles. The motor cortex and corticospinal tracts degenerate in ALS. Illustration used with 
permission of Elsevier Inc. All rights reserved. 
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1.3 CLINICAL PRESENTATION 
1.3.1 Presenting signs and clinical course of ALS 
The ALS weakness is insidious and the initial indications of weakness may be noted in 
a limb, an arm more often than a leg, or in muscles of speech and swallowing. The grip 
of the hand is not as firm as it used to be. Tasks demanding sustained heavy muscle 
effort like using a hammer or an axe or whipping an egg by hand are found difficult. 
The patient may lose items, crash a coffee cup or be unable to use the door keys. When 
the leg is affected first stumbling over very low hindrances such as the edge of a mat or 
a low threshold is noted. Rising from a chair may not come as easy as it used to and in 
athletic exercises such as long distance running you may unexpectedly trip over and 
fall. In retrospect many ALS patients can ascribe accidents of falling or tripping to early 
signs of the disorder. In the bulbar presentation problems pronouncing certain vowels 
and a sensation of the tongue being thick in the mouth are early signs and swallowing 
may be difficult. 
 
Early signs of ALS may be misdiagnosed as general weakness or assigned to some 
other more common cause of peripheral nerve affection, such as nerve root affection, 
myopathy, polyneuropathy or a peripheral nerve entrapment. Involuntary small local 
muscle contractions i.e. fasciculations are often seen in an anatomically widespread 
fashion. The weakness may spread to the contralateral limb or spread from arm to leg 
finally and invariably reaching the diaphragm causing respiratory weakness. Drooling 
is a consequence of impaired swallowing and may pose a substantial problem. 
Coughing follows respiratory weakness and congestion of viscous mucus is a 
consequence of difficulties in coughing. Pneumonia is the most common cause of death 
in ALS after a period of increasing respiratory paresis.  
 
 
1.3.2 Differential diagnosis of ALS 
Amyotrophic lateral sclerosis is an always fatal disorder and proper diagnosis is 
important, as diagnostic errors have vast consequences. Progression is a necessary 
diagnostic criterion of ALS, however not always easy to evaluate. Other conditions 
presenting with painless muscle weakness may follow the same time course and show 
the same clinical picture as ALS. Diagnostic mistakes can be made in both directions 
i.e. excluding ALS in a patient where typical ALS features becomes more evident with 
time, or erroneously making the diagnosis of ALS in a patient with another disease.  
 
The most common differential diagnoses are myopathies that present with both muscle 
atrophy and widespread muscle weakness as in ALS. Some other conditions that may 
present a diagnostic challenge towards the ALS diagnosis are myasthenia gravis, 
poliomyelitis and multifocal motor neuropathy with conduction block, some 
polyneuropathies, multiple radiculopathy, brain stem infarction and Kennedy disease. 
 
 
1.3.3 Neurophysiological diagnosis of ALS 
Myopathic conditions may present clinically indistinguishable from ALS and many 
other conditions with muscle atrophy and weakness mimic ALS.  Electrodiagnostic 
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methods are necessary for diagnosis. Electromyography (EMG) is a sensitive method to 
detect ALS pathology (Daube 2000) and positive sharp waves indicating denervation 
can often be seen in the EMG several months or years before clinical symptoms 
emerge. Unstable very high amplitude and long duration motor unit potentials are 
found in ALS together with signs of simultaneous reinnervation. Denervation potentials 
are noted in several muscles within the same myotome in one limb, spreading to the 
contralateral limb or to another segment. Often the EMG investigation is repeated to 
ensure progression with spread of denervation before a final diagnosis. Some variations 
in this practice is noted in-between laboratories and the importance of electrodiagnostic 
standards in ALS diagnosis must be emphasized (Pugdahl et al. 2010).   
 
Neurographic studies may show reduced motor nerve amplitudes consistent with 
degeneration of the anterior horn cells and motor neurons. Disease progression can be 
followed using motor amplitudes. Methods for motor unit counting such as motor unit 
number index (MUNIX) are useful to monitor the progressive loss of motor units in 
ALS (Nandedkar et al. 2011). Sensory nerve conduction velocities and amplitudes are 
unaffected in ALS but motor nerve conduction studies can show slightly reduced nerve 
conduction velocities and pathologically delayed F-latencies (de Carvalho and Swash 
2000). 
 
 
1.4 OBSERVATIONAL STUDIES 
1.4.1 Population studies of ALS  
ALS is a disorder diagnosed in the elderly (Figure 3). Onset before the age of 40 is rare 
and incidence increases with age to peak at about 60-70 years of age. There is a male 
preponderance with a ratio about 4-1,5:1 varying between countries.  
Figure 3. Mean number of deaths from ALS in Finland from 1986 to 1995 in men and 
women in different age groups (bars). The overall population of men and women in 
different age groups are depicted by lines. From (Maasilta et al. 2001) with permission. 
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An increase in ALS incidence has been observed since the middle of the century 
(Lilienfeld et al. 1989) and the increase varies between regions and with size of the 
population studied. Annual incidence of ALS is high in Scandinavian countries recently 
estimated to 2.98 per 10
5
 in Sweden for the years 2003-2005 when adjusted for age 
(Fang et al. 2009), but low in Mexico with 0.4 per 10
5 
sometimes referred to as a 
“Mexican resistance” to the disorder (Olivares et al. 1972).  From Finland mortality in 
ALS has been constantly increasing over the years from 1963 to 1995 (Maasilta et al. 
2001). Norway report increasing mortality (Seljeseth et al. 2000), and the latest 
Swedish study (Fang et al. 2009) describes an annual increase in ALS of 2% per year 
from 1991 to 2005 (Figure 4). In previous studies from Sweden the age-standardized 
mortality from ALS in Sweden doubled from 1961 to 1985 (Gunnarsson et al. 1990).   
 
To what extent this observed ALS incidence increase in several countries depends on 
an increasing case ascertainment based on a better diagnostic assessment and extended 
neurological service, remains an open question. ALS is still a rare disorder and large 
population based studies involving cooperation between countries may be needed to 
answer the important question if ALS incidence, when adjusted for age and the 
expansion of diagnostic facilities, is actually increasing (Beghi et al. 2006). 
Figure 4.  Age-standardized incidence of ALS in Sweden. Age-standardized to the 
Swedish population in 1991, 1 per 100000 person-years, by sex and calendar period in 
Sweden, January 1, 1991 through December 31, 2005. From (Fang et al. 2009), with 
permission. 
Copyright restrictions may apply.
Fang, F. et al. Arch Neurol 2009;66:515-519.
Age-standardized incidence of amyotrophic lateral sclerosis (to the Swedish population in 
1991, 1 per 100 000 person-years) by sex and calendar period in Sweden, January 1, 1991, 
through December 31, 2005
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Some 10 % of ALS cases are of hereditary origin and show an association with some 
150 known mutation varieties in the gene coding for Cu/Zn superoxide dismutase 
(SOD1) (Prudencio et al. 2009). The interplay between possible environmental toxic 
causes of neurological disorders and genetic background polymorphism is complicated 
and the two aspects are further intercalated as possible epigenetic mechanisms for 
pathogenesis are being unveiled (Rooney 2011).  
 
In perspective of possible environmental agents e.g. metals, contributing to ALS 
pathology, the rate of incidence increase over decades is important to determine. 
Observations of an ALS incidence increase rate that parallels the rate of increasing 
environmental contamination support the idea of exposure to various toxicants as 
possible pathogenetic mechanisms in ALS, however data from several countries need 
to be weighted together in order to evaluate if environmental causes to the disease are 
valid.  
 
 
1.4.2 Occupational studies of ALS 
Occupations associated with an increased risk of developing ALS are agricultural 
workers, athletes, cockpit occupations, electrical workers, farmers, hairdressers, 
laboratory technicians, leather workers, machine assemblers, medical service workers, 
military workers, power production plant workers, programmers, rubber workers, 
tobacco workers and welders (Table 1). 
 
What do these defined occupations have in common? Clues to ALS pathogenesis and 
possible exposures can be extracted from these occupational data. The use of so called 
job exposure matrices, where standardized occupation coding is related to known 
exposures, have improved the specificity of occupational exposure studies, however 
these matrix methods are not without problems as occupational exposure situations 
often are unique for each individual. A detailed anamnesis performed by an expert 
panel with knowledge in environmental medicine or by an expert with training in 
chemistry may yield the most accurate exposure information (McGuire et al. 1997). 
 
A recently developed job-matrix specific for jobs exposed to electricity connected to 
the risk of developing ALS has addressed some of these problems (Huss et al. 2012). 
The method of self-reporting via questionnaires has several limitations (Stewart and 
Stewart 1994). Direct measurements of exposure are possible in occupational settings 
with known concentrations of the offending agent in e.g. inhaled air. Diurnal variations 
in exposure need to be correlated for and samplings at one point in time are less 
reliable. Exposure measurements in the general population are even more complicated 
and no data exist on premorbid exposures in ALS cases aside from anamnestic 
occupational informations. Exposure relevant to ALS can be expected to be protracted 
over several years or decades before diagnosis. Data from occupational exposures and 
their correlations to ALS are however informative and some associations into the 
population may be found.     
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Table1. Occupations at risk of developing ALS1 
Population Study Observations Statistic Reference 
ALS (n=105) 
Controls (n=164) 
C/C 
Job exposure to As, Mn, Hg or other metals  
significantly increased in cases 
p˂0.001 
Roelofs  
1984 
ALS (n=66) 
Controls (n=66) 
C/C 
Self-administrated questionnaire showed no 
association between metal exposure and ALS 
 
Gresham 
1986 
ALS (n=1961) 
Controls 
(n=2245) 
C/C 
Cluster of male cases in agricultural work. 
More female cases than expected were 
medical service workers 
3.4A 
 
1.7A 
Gunnarsson 
1992 
ALS (n=25) 
Controls (n=50) 
C/C Welding and soldering associated with ALS 5.0A 
Strickland 
1996 
ALS (n=174) 
Controls (n=348) 
C/C 
ALS associated to:  
-Agricultural chemicals in men  
-Manganese in men and women 
 
2.4A 
4.7A 
McGuire 
1997 
ALS (n=108) 
Controls (n=302) 
C/C 
Significantly higher ALS rates in industrial 
workers compared to white collar jobs 
2.81
A
 
 Kihira 2007 
ALS (n=335) Pop More ALS deaths among farmers 22% Bale 1975 
ALS Pop 
Higher ALS mortality in leather workers 
1959-1963 
16/8.7B 
p˂0.01 
Hawkes  
1981 
ALS (n=563) Pop 
Excess ALS deaths                      1970-1972 
in leather workers                        1975 
259C 
200C 
Buckley  
1983 
ALS (n=161) Pop 
More ALS patients among electrical 
workers, food, drink and tobacco workers 
and rubber workers 
 
Holloway  
1986 
ALS Pop Significantly higher risk in agricultural work. 5.28/105 Rosati 1997  
ALS (n=8) Pop 
Cockpit occupation correlated to 
significantly increased ALS mortality 
2.35D 
Nicholas  
1998 
ALS (n=143) Pop 
Higher ALS rates in mountainous areas. 
Significantly higher risk in agricultural work.  
 
22% 
Mandrioli  
2003 
ALS (n=20) Pop Increases ALS incidence in war veterans p=0.05 Haley 2003 
ALS (n=91) Pop 
Number of cases in agricultural work  
exceeded the expected number 
22/6B Govoni 2005 
ALS (n=937) Pop 
Elevated ALS mortality in programmers, 
laboratory technicians and machine 
assemblers 
p=0.009 
p=0.04 
Weisskopf  
2005 
Literature review Meta 
Occupational exposure to metals found in 
ALS 
 Matias 2008 
Thirteen selected 
studies 
Meta 
Consistent evidence linking electrical 
occupations to increased risk of ALS 
 
Kheifets 
2009 
Twelve selected 
studies 
Meta  
Increased ALS risk in veterinarians, athletes, 
hairdressers and power-production plant 
workers, electrical and military workers. 
 Sutedja 2009 
1
Different statistical methods have been used: A-Odds Ratio, B-Observed number/expected 
number, C-Standardized mortality ratio. D-Proportional mortality ratio. %-deaths in this category 
in % of total ALS deaths. Types of studies: C/C-Case control studies, Pop-Population studies, 
Meta-Meta analyses.                                       
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Some occupations are in several studies linked to an elevated ALS risk, most 
consistently agricultural work (Table 1), shown in both case control studies and 
population studies. A Japanese case control study found significantly elevated ALS risk 
in industrial workers (Kihira et al. 2007) when compared to white collar jobs. Workers 
in agriculture seems to be at risk for ALS (Govoni et al. 2005), in a few studies linked 
to the use of pesticides and herbicides (Mandrioli et al. 2003, McGuire et al. 1997). A 
study specifically asking about metal exposure with a self-administered questionnaire 
to 66 patients and to the same number of controls found no association between metal 
exposure and ALS (Gresham et al. 1986). Another study using questionnaires asking 
for occupational as well as other types of exposure in ALS patients found metals to be a 
common denominator (Roelofs-Iverson et al. 1984). 
 
In a detailed epidemiological study by Gunnarsson et al, patients with ALS and 
randomly selected controls from a national population register were compared, and 
odds ratios (OR) were found elevated for male electrical workers, welders and workers 
handling impregnating agents (Gunnarsson et al. 1992). Another smaller case-control 
study identified exposure to welding or soldering material as strongly associated with 
ALS occurrence but also mentioned electric plating, paint or pigment manufacturing, 
petroleum industry, printing industry and shipbuilding as risk occupations (Strickland 
et al. 1996). Working with electricity or within electromagnetic fields of varying 
strength has been associated with ALS in several studies (reviewed in (Kheifets et al. 
2009). A large cohort study (Feychting et al. 2003) found an indication (RR=1.4) of an 
increased risk for ALS among men working in the job category electrical and 
electronics work, but did not find an association between electromagnetic fields 
exposure and ALS.    
 
A meta-analysis showed metal exposure regardless of source as consistently associated 
with ALS (Matias-Guiu et al. 2008). Another very large systematic review covering all 
published studies on occupation as a risk factor for ALS used a critical classification of 
study methodology and could identify veterinarians and other health workers, athletes, 
hairdressers, power-production plant workers, electrical and military workers as 
candidate occupations associated with the risk of developing ALS (Sutedja et al. 2009). 
Military veterans have also been identified as being at elevated risk for ALS in two 
separate studies (Haley 2003, Weisskopf et al. 2005). 
 
In summary several seemingly disparate occupations have been associated with an 
elevated risk to develop ALS. Links to exposures to metals and exposures to 
electromagnetic fields can be extracted. 
 
 
1.4.3  Geomedical aspects 
From the discipline of medical geology (Selinus 2005) valuable information can be 
gathered concerning metals possibly affecting the nervous system. The existence of 
geographically isolated ALS clusters (Melmed and Krieger 1982, Neilson et al. 1994, 
Proctor et al. 1992, Sanders 1980) lend support to an environmental etiology for the 
disease. Statistically significant differences found in ALS incidence in counties next to 
each other (Imam et al. 2010) further support this notion. Clusters of ALS have been 
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described from regions with mining activity (Buckley et al. 1983, Mitchell et al. 1998, 
Mitchell et al. 1990)  and geological knowledge is important for the understanding of 
natural distribution of metals with neurotoxic properties. 
 
Clusters provide important clues to the possible causes of ALS. Some of the clusters 
could on statistical grounds be described as expected variations in ALS incidence in a 
uniform population but one accumulation of cases stands out by convincingly showing 
the highest ALS incidence ever described. In Guam, the Kii Peninsula in Japan, and 
Western New Guinea (Garruto and Yanagihara 2009) ALS incidence was found to be 
more than 50-fold higher than the worldwide incidence (Mulder and Kurland 1987). 
Environmental studies of soil and drinking water revealed elevated concentrations of Al 
and Mn and analysis of lumbar motor neurons from ALS cases from this region showed 
high contents of Al and Mn (Kihira et al. 1995). Aluminum was found to accumulate 
within DNA-containing chromatins and rRNA-containing cellular components leading 
to nerve cell death. Aluminium, Mn and other metals, or mineral/metal imbalances, 
have been implicated in these pacific hyperendemic foci of ALS (Gellein et al. 2003, 
Yase 1972) . 
 
In southeast of Finland significant clusters of ALS have been identified in a large study 
using spatial-scan statistics examining both time of birth and time of death (Sabel et al. 
2003). Different clusters were found for time of birth and time of death however all 
clustering was localized in the southeast region. The authors discuss the possibility of a 
genetically susceptible subpopulation in the area but also speculate in the possibility of 
clustering related to metal polluted lakes in the region and various other environmental 
offenders. Geological conditions lowering pH of rivers in Finland causing leach of 
metals into the echosystem (Astrom 2000) may also contribute to neurodegenerative 
disorders.  
 
The reports (summarized in (Caller et al. 2012)) on spatial clustering in ALS are varied 
and describe accumulations of cases in buildings, counties, proximities to lakes or 
rivers or war zones and several other specific but highly scattered conditions.  
ALS incidence is also unevenly distributed across geographical regions. Such variation 
may be explained by a genetic predisposition for ALS among certain ethnical groups 
(Cronin et al. 2007).  It could also be understood as an effect of geographical variations 
in the distribution of substances toxic to the nervous system. Efforts to analyse this 
variation in terms of one specific offending agent have largely failed (Caller et al. 
2012), but geographical covariation between ALS and the geographical occurrence of 
metals is a possible scenario worth further exploration in collaborations with the 
geological scientific community. In summary geomedical data lend further support to 
the possibility of metals contributing to ALS pathogenesis. 
 
 
1.4.4 Animal observations  
The complex mechanisms responsible for metal exposure and accumulation in tissues 
and body fluids are the same for animals and human beings. If the symptoms of ALS 
are manifestations of intoxication and the toxicants, regardless of their origin, are 
widespread globally then effects in animals are to be expected. Can ALS be found in 
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animals? An overview of data on animals developing fatal muscle weakness and 
wasting is given here. Connections to metal exposure are described. 
 
1.4.4.1 ALS-like states in animals 
Humans are part of local ecosystems in the same way as animals are and clues to 
human ALS causation can be found in animal observations. Animals with fatal 
widespread muscle weakness, wasting and fasciculations have been observed. 
Domestic animals like horses and cattle encounter syndromes comparable to human 
ALS and similar degenerative states have been noted among various species.  
 
In horses MND was first described in the US (Cummings et al. 1990) (Figure 5) and 
has also been observed in horses in England and Japan (Kuwamura et al. 1994). This 
equine motor neuron disease (EqMND) (Divers et al. 1994) shows histopathological 
changes  of the spinal cord comparable to the changes in anterior horn cells of the 
spinal cord in human ALS (Cummings et al. 1993) . Symptoms, progression rate and 
distribution of weakness and atrophy closely resemble what is found in the human 
variety.  
 
 
 
 
Thus both human beings and horses encounter MND. The equine cases are sporadic 
and show an uneven geographical distribution (de la Rua-Domenech et al. 1995)  with 
regions of increased risk, comparable to the geoclustering found in human SALS 
(Caller et al. 2012, Doi et al. 2010) . Wildlife animals with limb weakness and muscle 
atrophy also provide clues into possible environmental etiologies to ALS, especially 
when found in clusters that can be linked to a possible exposure. Domestic and wild 
animals have been observed with slowly progressive fatal muscle wasting and 
Figure 5.  Equine motor neuron disease. Head is held low and muscle wasting is 
prominent. Photo courtesy prof. T.J. Divers 
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weakness. Similarities to human ALS has been pointed out by veterinarians studying 
these animals. 
 
Severe skeletal muscle atrophy and death have also been observed in domestic animals. 
Selective search for metal intoxications, most often in liver and blood, rarely in CSF,  
have shown normal metal levels, however the distribution of histopathological changes 
in these animals, closely resembling the distribution in human ALS, have drawn the 
attention towards possible common etiologies. Degeneration and loss of motor neurons 
in the ventral horns of cattle was found together with accumulation of neurofilaments 
and mitochondria in animals showing severe muscle atrophy (el Hamidi et al. 1990) . 
Microscopic studies of the spinal cord and brain in older Swiss-Brown cattle (Troyer et 
al. 1992) showing muscle atrophy including tongue atrophy demonstrated extensive 
necrosis of lower motor neurons and extensive upper motor neuron degeneration and 
descending tract pathology, as in human ALS. Massive accumulations of 
neurofilaments were found in ventral horn cells in pigs. A 6-week-old Hampshire pig 
with progressive weakness was examined and axonal degeneration was found in ventral 
spinal nerve rootlets and peripheral nerves. Neuronal swelling and pallor identical to 
those in the spinal cord were observed in the brain stem. Areas affected included 
oculomotor nucleus, vestibular nucleus, reticular formation, and hypoglossal nucleus. 
Hepatic Cu, Se and Zn levels were normal (Montgomery et al. 1989).  
 
 
1.4.4.2 ALS-related metal exposure experiments in animals 
Metal exposure experiments in animals have shown widespread muscle weakness, 
fasciculations and atrophy as in human ALS. Anterior horn cells and motor axons are 
most often beset by these exposures.  
 
In an experiment (Divers et al. 2006) to uncover possible causes of EqMND horses 
(n=8) were fed elevated levels of copper (Cu) and iron (Fe) and low vitamin E and 
compared to horses (n=51) fed regular levels of Cu and Fe and vitamin E. The horses 
were kept together and observed for more than 22 months. Half of them, four horses, in 
the Cu/Fe/lowE fed group developed EqMND with fasciculations, muscle atrophy and 
death. No horse in the control group developed the disorder. 
 
In another horse study concentrations of several metal species were measured with 
ICP-MS in spinal cords from horses (n=24) with EqMND and compared to control 
horses (n=22) without the disorder. Copper concentrations were significantly higher in 
EqMND spinal cords (Polack et al. 2000). No other metal showed elevated 
concentrations. Metals measured were Mg, Cu, Fe, Mn, Ni, Zn, Al, Co, Cr, Pb, Cd, Hg 
and Se. 
 
Feeding experiments can not be conducted in humans but Cu/Fe feeding in horses 
seems to precipitate EqALS. Extended studies of metal concentrations in tissue and 
CSF from horses with EqMND would be of value to forward the knowledge of metals 
as possible causes of motor neuron degeneration. Regular use of vitamin E supplements 
have been associated with reduced risk of dying of ALS in a large human study 
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(Ascherio et al. 2005). Copper  concnetrations are recently found elevated in human 
Alzheimer´s disease (AD) body fluids (Ventriglia et al. 2012).   
 
Horses intoxicated with Pb showed widespread fasciculations, muscle weakness and 
weight loss and were initially diagnosed as EqMND, however recovered upon 
treatment for Pb intoxication. Those horses had by accident been eating Pb paint chips 
containing 0.1 % Pb (Sojka et al. 1996).   
 
Leghorn chicken (n= 12) were fed Pb acetate gelatin capsules in increasing doses up to 
170 mg/kg bw. The chicken developed muscle weakness and atrophy. Sections of the 
spinal cord showed anterior horn cell degeneration. Lead concentration in spinal cord 
was 6.5μg/g. A syndrome was produced by Pb feeding, characterized by a fall in motor 
response amplitude, spinal motor neuron degeneration, motor axonal loss and atrophy 
of muscle, similar to that seen in human MND (Mazliah et al. 1989). 
 
When rabbits were injected intathecally with aluminium (Al) salts ventral horn axonal 
swellings persisted after exposure and axonal neurofilament accumulation was detected 
during Al exposure (Troncoso et al. 1982). Anterior horn cell pathology with 
chromatolysis, accumulation of neurofilaments and axonal swelling was also seen in 
monkeys fed for one year with low Ca and low Mg diet with Al lactate added to the 
drinking water producing elevated Al concentrations in the bloodstream (Yase 1987).  
 
In the wild, clusters of animals showing widespread lethal muscle atrophy have been 
observed. Tissue metal studies are scarce in these wild animals and only restricted 
comparisons towards human muscle atrophic disorders can be made. High 
concentrations of Mb and Cu was found in wild moose with severe muscle wasting 
dying in the Swedish county of Älvsborg (Frank 2004). Metals, notably Cd and Pb, 
have been shown to accumulate in tissue from Karelian reindeer and other wildlife 
animals and concentrations of these metals increase with age. Dietary habits and 
atmospheric exposure are the most prominent metal sources (Medvedev 1999). 
Elevated systemic manganese (Mn) concentrations have recently been detected in deer 
liver tissue from clustered animals showing widespread muscle atrophy (Wolfe et al. 
2010). 
 
Several other animals reproduce structural or physiological aspects of human ALS. A 
review covering 38 animal species describes some of these connections and their 
relation to, or lack of, metal exposure data (Sillevis Smitt 1989) . In summary lethal 
animal disorders with wasting and weakness, closely resembling human sporadic ALS, 
exist in several animal species and links to metal exposure can be found. 
 
 
1.5 ETIOLOGY 
Suggested etiologies for nerve cell degeneration in ALS include genetic, viral, 
metabolic and toxic mechanisms as well as impaired neurotransmitter function. There 
is evidence for an increase in prevalence of neurodegenerative disorders in the 
population in the US (Lilienfeld et al. 1989, Noonan et al. 2005, Sejvar et al. 2005) 
and Europe (Chio et al. 1993, Maasilta et al. 2001, Seljeseth et al. 2000). 
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Observational studies support the idea of environmental causes to the observed 
increase rate in ALS incidence (Clark 2005). Other pieces of evidence pointing in the 
direction of external causes to the disease are the existence of animals with ALS-like 
atrophy and weakness, the clustering of human ALS cases in contaminated regions of 
the world, ALS being more common in certain occupations as well as the existence of 
conjugal clustering of ALS. 
 
An always lethal disorder with a cause unknown for more than a century provokes 
many theories on etiology. Many therapeutical trials emerging from a new idea on 
disease causation have failed in curing ALS or even in halting the progression of the 
disease. A thorough understanding of ALS etiology in terms of patophysiology, 
electrophysiology and chemistry is needed before attempts to administrate any 
medication are made. The rule of causal diagnosis first and treatment trials later 
certainly applies to ALS.  
 
Several different organ systems are simultaneously involved in ALS pathology and any 
environmental proposal concerning the cause of this disorder need to take into account 
these coexisting affections. Within the nervous system the frontal lobes are affected 
(Abrahams et al. 2005) in some cases and involvement of the autonomous nervous 
system (ANS) may affect cardiovascular regulation, gastrointestinal and salivary gland 
regulation and cause sympathetic hyperactivity in ALS patients (Baltadzhieva et al. 
2005). Other systems outside of the nervous system are also affected and ALS-specific 
skin changes (Fullmer et al. 1960) with connective tissue abnormalities, elastosis and 
collagen alterations have been described (Ono et al. 1998). Ultrastructural 
investigations indicate mitochondrial abnormalities in keratinocytes from ALS skin 
(Rodriguez et al. 2012).  Cardiomyopathy has been noted in ALS (Gdynia et al. 2006, 
Matsuyama et al. 2008) , although circulatory problems are not prominent clinical 
features of the disorder. Liver dysfunction and liver ultrastructural changes (Fisman 
1987) exist in ALS and liver biopsies from ALS patients show hepatocytes with 
mitochondrial changes and intramitochondrial paracrystalline inclusions, described as 
specific to ALS. At the ultrastructural level mitochondria in cells from several organ 
systems have shown structural abnormalities in ALS (Menzies et al. 2002, Sasaki and 
Iwata 1999). 
 
This multisystem nature of the disorder provides some etiological clues and prevailing 
theories on ALS etiology cover some of these simultaneous affections of different 
organ systems. Any etiological theory needs to explain multisystem pathology. Several 
etiological aspects have emerged, including affections of cell organelles. The existing 
evidence for glutamate-mediated excitotoxicity, altered neurofilament and peripherin 
expression, disrupted axonal transport, neurotrophin deficiency or mitochondrial 
alterations may all need consideration. 
 
As yet, no consensus has been achieved on the mechanisms that lead to selective motor 
neuron death in ALS, and the underlying causes are still unknown for the vast majority 
of patients. Further clues about genetic susceptibility and environmental triggers are 
important to increase knowledge about the pathogenesis, which may help in the 
development of prevention and more effective treatment for ALS (Shaw et al. 2001). 
The following factors cover the most discussed existing theories on the cause of ALS: 
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Genetic factors: Alterations affecting the Cu/Zn superoxide dismutase (SOD1) enzyme 
accounts for about 10% of ALS cases described as familial ALS (FALS). More than 90 
individual mutations in SOD1 have been described as being responsible for FALS 
(Valentine 2002). No evidence exists for genetic causes of sporadic ALS, which has 
shown a steadily increased mortality frequency throughout the century (Kurtzke 1982). 
This increase may reflect increased awareness and improved access to diagnostic 
facilities such as EMG. The increase is, however, of a magnitude that excludes genetic 
migration and has been interpreted from epidemiologic data alone to support an 
environmental etiology (Lilienfeld et al. 1989). New findings of possible genetic 
correlations in patients with the C9orf72 mutation to an ALS phenotype with frontal 
lobe dementia (Andersen 2012) have brought genetic factors to the fore. A recent very 
large meta-analysis of genome-wide associations largely failed in associating risk gene 
variants with sporadic ALS. One locus at 1p34.1 modulating age of ALS onset was 
however identified. Considerable genetic heterogeneity within the ALS clinical 
phenotype seems to be present. The genetic influences on sporadic ALS can be 
described as weak (ALSGEN 2012). 
 
Viral factors: Herpes virus type 8 has been associated with ALS in some studies, 
although these links remain to be proven. Recent efforts to detect enterovirus, including 
poliovirus in ALS by reverse transcription–polymerase chain reaction, have failed. An 
association between some MNDs and human immunodeficiency virus (HIV) infection 
is not coincidental, but pathogenetically related, and ALS-like disorders have been 
proposed to be an HIV-related neurological complication (Moulignier et al. 2001). 
  
Inflammatory factors: Actions of cyclo-oxygenase-2 and prostaglandins in central 
nervous system (CNS) inflammation have gained some attention in ALS. Other 
inflammatory etiologies including microglia activation have been proposed. Similarities 
between ALS and the inflammatory disorder multiple sclerosis (MS) have been 
emphasized by some authors who discuss common mechanisms of axonal degradation 
(Coleman et al. 2005). A high correlation between mortality due to MS and ALS exist 
as judged from Swedish epidemiological data (Landtblom et al. 2002); however, no 
common etiopathological theory has yet emerged. 
 
Oxidative factors: Postmortem studies have proposed oxidative injury by oxidative 
damage to proteins, lipids, and DNA, although the initiating causes of these events have 
not been identified (Agar and Durham 2003). Markers of oxidative damage have been 
found elevated in ALS tissue (Beal 2002). Polymorphisms in anti-oxidative enzymes 
(Forsberg et al. 2001), some of them possibly involved in ALS pathogenesis, have been 
described. 
 
Toxic factors: Substances of many kind have been suggested to contribute to ALS, 
including pesticides and herbicides, rotenone, cocaine, amphetamine, and electrical 
injury, as well as cockpit occupation (Brooks 2000a). Other chemicals, including  
formaldehyde (Weisskopf et al. 2009) and solvents (Pamphlett 2012), as well as 
smoking (de Jong et al. 2012) have also been associated with ALS pathogenesis. In 
contrast, alcohol consumption was associated with a reduced risk of ALS (de Jong et al. 
2012). Metals such as Cd, Hg and Pb, which are constituents of cigarette smoke 
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(Rickert and Kaiserman 1994), and arsenic (As) in the form of lead arsenate 
(PbHAsO4), which  has been used in pesticides (Delistraty and Yokel 2012), have been 
suggested to be associated to ALS pathogenesis. A study by the ALS CARE study 
group could not confirm toxic metal exposure at work as a significant risk factor for 
ALS (Brooks 2000a). However, a detailed review covering toxic factors and other 
previous etiological considerations in ALS presents the hypothesis that there is a 
causality between metal toxicity and ALS (Roos et al. 2006).  
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2 METAL EXPOSURE 
 
The effects of acute metal exposure are well described for many different metals 
(Nordberg et al. 2007a). This kind of exposure may occur in environmental accidents 
(Skerfving and Copplestone 1976) or occupational exposure associated with metal 
handling such as welding (Sjögren et al. 1996) or smelting. In those situations toxic 
effects are fast and often dramatic and, if the patient survives, restitution is observed 
and is sometimes although not always, complete. Concentrations of metal in tissues 
drop back to safe levels and, if repeated exposure is avoided, no permanent damage can 
be traced. 
  
Less is known about low dose long time exposure where repeated small doses of the 
toxic metal eventually may override excretion capacity causing accumulation in tissues 
(Needleman et al. 1990). Muscle atrophy and muscle weakness have been described 
after exposure to some metals and several metals cause fasciculations (see 3.4.8 below). 
Combinations of metal exposure to the nervous system may contribute to various 
degrees of these symptoms, as found in ALS. 
 
 
2.1 EXPOSURE ROUTES 
Low dose long time metal exposure in humans can be expected to be complex, varied, 
insidious and unpredictable. Metals can make contact with the human organism 
through several media such as air, food and water, or by material injected, infused or 
implanted. In industrialized regions with heavy air pollution respiratory exposure can 
dominate whereas in rural or mountain regions metals such as As or U are naturally 
present in soils and rock formations presenting a background exposure (Nordberg et al. 
2007a) . Food can be the major exposure medium in a variety of circumstances, 
including accidental contamination and dietary habits such as mercury (Hg) exposure in 
populations dependent on fish or marine mammals from contaminated areas as their 
major source of protein. These exposures form a complex web unique for each 
individual depending on region of birth, sources of water and food, occupational 
exposures, geographic circumstances at place of birth (Sabel et al. 2003), surgical 
procedures, medical treatments and other specific exposures of unexpected and varied 
nature. In evaluating possible metal exposure in an ALS patient it is important to cover 
a lifetime anamnesis as low dose long time sources easily can be overseen. 
Accumulations can be expected to cause the age distribution seen in this disorder, with 
peak incidence late in life (Figure 3). 
 
Possible routes of metal exposure need to be considered separately as multiple 
exposures can use several different routes, and background information on these routes 
in relation to neurodegeneration is provided here in some detail. 
 
Respiratory: Inhaled metals can occur in the form of vapor or dust. Metal particle size, 
charge and form determine where in the respiratory system they are deposited, which 
influences absorption rate. Pb containing aerosols are still a concern in some countries 
where leaded gasoline is in use, or organomanganese compounds that are used as 
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modern gasoline additives. As and Pb can be found in fly-ash piles from coal fired 
power plants. Smoking is a major source for respiratory exposure to Cd and Hg among 
other metals. Industrial exposure to metals via the respiratory route is found in 
smelting, welding, grinding and cutting producing metal aerosols (Nordberg et al. 
2007a) . For some metals e.g. Hg the respiratory route causes significantly higher tissue 
levels than the intravenous route (Berlin et al. 1969). 
 
Enteric: Drinking water is a major source of possible metal exposure. In some 
geographical regions metals occur naturally in groundwater and agricultural processes 
or soil conditions (Fältmarch 2008) may elevate metal concentrations in drinking water. 
Arsenic containing water wells have exposed millions of people in Bangladesh 
(Chakraborti et al. 2010, Kippler et al. 2012)  , causing a syndrome with muscle 
atrophy (McCutchen and Utterback 1966) and sometimes fasciculations (Mazumdar et 
al. 2010) among other manifestations. Concerns with Cu water piping in conjunction 
with dementia have been described (Brewer 2010). Various food sources may be metal 
contaminated, by industrial processes or methods of food processing. Arsenic 
containing beer and wine has been produced and cereal based products, algae, bottled 
water, coffee, rice, fish and vegetables are also sources of As, possibly entering the 
human organism via the enteric route. The use of metal rich sewage sludge as fertilizer 
and conditions (Fältmarch 2008, Nordberg et al. 1985)  lowering the pH of soils 
increasing the leach of metals also contribute to metals finding their way into food.  
 
Dermal: Significant metal uptake through the skin has been described for cobalt (Co) 
and for thallium compounds (Nordberg et al. 2007a). Dermal exposure to Hg has been 
described for dental personnel (Svendsen et al. 2010). A case of fatal central nervous 
system toxicity following transient dermal exposure to dimethylHg is well documented 
(Nierenberg et al. 1998). The finding of an ALS cluster of Italian soccer players could 
possibly be linked to dermal exposure to metal containing grass fertilizers (Chio et al. 
2005). 
 
Axonal: Transport of metals in the axoplasmatic flow in the retrograde direction has 
been described for many metals (Arvidson 1985, Arvidson 1994, Tjalve and 
Henriksson 1999). Selective accumulation of Hg in spinal and brainstem motorneurons 
after intramuscular injection of Hg chloride has been noted (Arvidson 1992) , 
demonstrating the efficiency of the retrograde axonal transport route. These 
accumulations could also be prevented by ligation of the peripheral nerve responsible 
for the transport. Selective axonal transport to secondary olphactory neurons and 
further migration into the telencephalon has been demonstrated for Mn after application 
of the metal in the ophthalmic chamber of pikes (Tjalve et al. 1995). Transport of Al 
into the cerebral cortex, hippocampus and olphactory bulb through nasal-olphactory 
pathways has been demonstrated in rabbits (Perl and Good 1987). The possible 
importance of the olphactory retrograde axonal transport pathway in humans with ALS 
is emphasized by the fact that secondary olphactory neurons project to the frontal lobe, 
affected in some ALS cases. 
 
Enteric/Respiratory: Amalgam restorations of teeth release small amounts of Hg 
vapour or Hg ions contributing to the amount swallowed or inhaled  (Brune and Evje 
1985). This release contributes to the exposure of the population to Hg (WHO 1991). 
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Intravenous: Direct access to the bloodstream via intravenous route, including infusion 
treatments, may cause metal exposure to nerve cells via inward directed transport 
mechanisms across the blood brain barrier (BBB) (Zheng et al. 2003). Deliberate 
intravenous injections of Mn in the potassium permanganate form by drug addicts have 
produced PD-like states with pronounced Mn accumulations in basal ganglia of the 
brain (Varlibas et al. 2009). Manganese intoxication during parenteral nutrition has 
been described to cause parkinsonism and Mn accumulations in the basal ganglia 
(Ejima et al. 1992). ALS has been described after accidental injection of Hg (Schwarz 
et al. 1996). Implants such as intramedullary nails or prosthetic devices constitute a 
special form of direct metal-to-blood contact causing systemic mobilization of 
implanted material into the bloodstream producing toxic effects (Mao et al. 2011). 
 
Possible degeneration of anterior horn cells from exposure to metals must be viewed in 
a broad environmental context where every patient has her unique individual pattern of 
exposure depending on place of birth, type of education, occupation, interests, sources 
of water and food etc. Early life metal exposures add to these calculations. Metals 
reaching the systemic circulation through any of the exposure routes discussed above 
can pass the barrier systems between blood and CSF and are candidates for anterior 
horn cell toxicity. Repeated daily exposure even in low doses from various sources 
must be taken into consideration when the individual combined exposure is evaluated 
and all possible exposure routes be assessed separately. 
 
 
2.2 DISTRIBUTIONAL STUDIES 
2.2.1 Retrograde axonal transport of metals to the spinal cord 
Metals transported in axons follow the axoplasmic flow and thus travel in both 
directions, to and from the cell body of the neuron. This retrograde flow is of particular 
interest in possible ALS pathogenesis as it provides a route for neurotoxic metals from 
the periphery to the anterior horn cells, known to degenerate in ALS. Other exposure 
routes depend on the systemic circulation for transport of metals to the barrier systems 
protecting the brain and spinal cord. Animal experiments using different metal 
exposure routes have been performed and show accumulations of metal in motor nuclei 
and axons. 
 
Cadmium. Radioactively labelled cadmium(Cd) injected into the tongue of rats (n=5) 
was accumulated in the hypoglossal nuclei as shown by autoradiography (Arvidson 
1985). The metals travel via an exposure route involving retrograde transport of Cd in 
the axoplasmal flow from the peripheral tongue muscle centrally into motor nuclei of 
the brain stem. Brain stem motor nuclei degenerate in bulbar ALS. 
 
Manganese. Studies on Mn uptake from the nasal epithelium via olphactory axons into 
the brain have shown that  metal moves relatively freely from the nasal cavity to the 
brain in a dose dependent manner and that Mn via this route can reach the spinal cord  
(Henriksson et al. 1999). This axonal olphactory pathway has considerable capacity to 
transport Mn into the nervous system and may be related to the neurotoxicity of inhaled 
Mn (Henriksson et al. 1999). Axonal transport of Mn and other metals has also been 
described in detail in pikes (Gottofrey and Tjalve 1991, Tjalve et al. 1995). 
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Aluminium. Peripheral injection of Al chloride into the subperineurial space of rabbit 
sciatic nerve caused degeneration of spinal motor neurons after exposure. Electron 
microscopy unveiled increased accumulation of neurofilament and free ribosomes, 
swelling, fragmentation of granular endoplasmic reticulum and lipid droplets in the 
motor neurons. Retrograde transportation of Al from the periphery to the anterior horn 
cells of the spinal cord was demonstrated (Kihira et al. 1995). 
 
Lead. Radiolabelled Pb was injected directly into rat triceps surae muscle and 
retrograde axonal transport along the sciatic nerve could be shown (Baruah et al. 1981). 
A metal transport rate of 10mm per day was calculated and the injected Pb reached the 
spinal cord after 9 days. 
 
Mercury. Intramuscular injections of Hg resulted in ipsilateral accumulations of Hg in 
ventral horn motoneurons of rats after 2 days. Mercury deposits were still present when 
the animals were allowed to survive 100 days. The anterior horn cell Hg staining was 
suppressed by ligation of the sciatic nerve. These findings indicate that Hg was 
transported retrogradely in axons of ventral horn motoneurons (Schionning 1993a) . 
Radioactively labelled Hg injected into the tongue of rats (n=8) was accumulated in the 
hypoglossal nuclei as shown by autoradiography (Arvidson 1987). 
 
 
2.2.2 Mercury accumulation in the spinal cord 
Ingested, injected or inhaled Hg accumulate in anterior horn cells of the spinal cord but 
not in surrounding spinal cord tissue after Hg exposure of  primates (Roos and Dencker 
2012a) and rodents (Pamphlett and Waley 1996, Schionning et al. 1993b, Stankovic 
2006, Su et al. 1998) (Figure 6). 
 
In the study by Stankovic Hg was distributed to ventral horn motor neurons but not to 
astrocytes (6A). Transverse section of mouse cervical spinal cord shows black granules 
representing inorganic Hg in the cytoplasm of the ventral horn motor neuron perikarya, 
but not in astrocytes and other motor neurons that were not from the anterior horn. 
Enlarged section below shows metal deposits (black arrow) throughout the cytoplasm 
of the motor neuron  
 
Schionning noted in rat spinal cords after respiratory exposure to Hg that groups of 
motor neurons in the ventral horn were heavily loaded with coarse silver-enhanced Hg 
grains and the staining was confined to the cytoplasm of the neurons (6B). Ventral horn 
motoneurons were heavily stained in all of the spinal cord segments and motorneurons 
containing numerous cytoplasmatic Hg grains were observed. 
 
Specifically Su et al noted atrophic cells and almost complete loss of large motor 
neurons with gliosis in the anterior horns, whereas small to medium-sized neurons were 
well preserved in mice 18 days after oral exposure to a high dose methyl-Hg. 
Phagocytosis of motor neurons was observed and Hg accumulations in large motor  
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neurons of the spinal cord were also noted (6C). A silver acetate autometallography of 
the L4 anterior horn from MeHg treated rat shows large motor neurons (arrows) that 
contain fine granular deposits representing silver-coated mercury deposits, whereas 
small to medium-sized neurons (arrowheads) show no such deposits 11 days after 
methylmercury treatment. 
 
Pamphlett found Hg granules within cell bodies of large lateral motor neurons in 
cranial nerve nuclei and the anterior horn of all spinal cord levels, sometimes also in the 
neurites (6D) in mice injected with Hg chloride and perfused after 5 days. Black 
granules of silver surrounding mercury deposits in the cell bodies and processes (arrow) 
of motor neurons in the anterior horn of the spinal cord were seen. 
 
Distribution to anterior horn cells and motor axons of metals with neurotoxic properties 
after exposure through various exposure routes in several experimental animals has 
thus been shown in several different studies. Inhaled Hg in the form of vapour has been 
demonstrated in anterior horn cells in rodents and the question arises if this is true also 
in primates? Accumulation of Hg in motor neurons of the spinal cord in a primate after 
respiratory exposure to Hg vapour is addressed in (Paper III, section 3.4.3). 
Figure 6. Mercury distribution in rodent spinal cord anterior horn cells after single dose Hg 
exposure. Details in text. Reproduced with permission from the publishers. 
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2.3 PREVIOUS STUDIES INVESTIGATING METALS IN ALS 
Spinal cord tissue: Direct measurements of metals in ALS spinal cord using various 
methods have in different studies shown significantly increased concentrations 
compared to controls of Mn, Al, Fe, Se, Zn, Pb and Cu (Table 2). 
 
 
Table 2. Metal concentrations in sporadic ALS spinal cord tissue 
Tissue section Size Method Metal  Concentration µg/g p Reference 
    ALS Controls   
Transverse 
 
7 ALS 
6 controls 
NAA1 Mn 1.75 1.02 <.001 Miyata 
1983 
Spinal cord 
anterior part 
4 ALS 
5 controls 
ICP2 Mn .41 .39 NS Kihira 
1990 
Spinal cord 
anterior horn 
12 ALS 
5 controls 
PIXE3 Al 25:1* 1:1* <.05 Kihira 
1991 
Ventral horn  5 ALS 
5 controls 
Laser probe 
MS
4 
Fe 
Al 
268 
2.90 
154 
4.03 
NS 
NS 
Kasarski 
1995 
Transverse 38 cases 
22 controls 
NAA1 Fe 
Se 
Zn 
19 
.142 
9.5 
14 
.100 
8.3 
<.0009 
<.0001 
<.042 
Marksbry 
1995 
Ventral horn 7 ALS 
12 controls 
Photon 
X-ray5 
Pb 
Cu 
Fe 
40.7 
89.0 
101.1 
14.6 
46.3 
53.7 
<.05 
<.05 
<.05 
Kurlander 
1979 
1
NAA: Neutron Activation Analysis. 
2
ICP: Induction Coupled Plasma 
3
PIXE: Proton induced X-
ray emission. * The PIXE method measures relative metal concentrations related to a baseline 
level. 
4
Laser probe MS: Laser microprobe mass spectrometry. 
5
Photon X-ray: Photon excited 
energy dispersive x-ray analytical system. 
 
Manganese concentrations in spinal cord transverse sections from 7 ALS patients were 
measured with neutron activation analysis and compared to 6 controls (Miyata et al. 
1983). Significantly (p<0.01) higher concentrations of Mn compared to controls were 
found. The highest Mn concentrations in ALS cases were found in the anterior horn and 
lateral columns. A study of Mn concentrations in ALS spinal cord separated into 
anterior horn, posterior fasciculus, posterior horn and posterior fasciculus showed 
higher Mn concentrations in the anterior horn part of the cord, however no difference of 
mean Mn content compared to controls (Kihira et al. 1990). Direct measurements of 
several metals in ALS spinal cord sections using PIXE showed significantly (p<0.001) 
elevated concentrations of Al compared to controls (Kihira et al. 1991). Another PIXE 
study found significantly increased Al concentrations in ALS frontal lobe tissue and 
signs of frontal lobe calcification (Yoshida et al. 1989). A follow up study from another 
laboratory using laser microprobe mass spectrometry could not confirm these findings 
(Kasarskis et al. 1995). Studies on bulk ALS spinal cord samples have shown increased 
Fe concentrations (Ince et al. 1994). Another autopsy study (Kurlander and Patten 
1979) found significantly (p<0.05) elevated levels of Pb, Cu and Fe in dissected spinal 
cord anterior horn sections from ALS patients compared to controls. A proton excited 
x-ray analytical system was used. The Pb values increased with duration of illness. 
Patients with the histories of greatest environmental exposure to metals during life also 
exhibited the highest metal levels after death (Kurlander and Patten 1979). A small 
study comparing 5 ALS patients to 5 diseased controls found significantly increased 
Mn concentrations in ALS spinal cords (Mitchell et al. 1986), as did a study of ALS 
spinal cords using neutron activation analysis (Lee 1994) .  
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Extraneural tissues: Kidney and liver tissue from ALS patients was studied with 
neutron activation analysis. Iron concentration was found significanty increased in ALS 
kidney compared to controls. Cobalt and Fe was elevated in ALS liver tissue. Mercury 
was also elevated in kidney and liver (Tandon et al. 1995). Hepatic Mn concentration 
was reduced in ALS patients but spinal cord Mn levels were increased both at the 
cervical and thoracic level (Mitchell et al. 1991). An influence on parathyroid function 
has been suggested from chronic environment Ca and Mg deficiencies resulting in 
increased intestinal absorption of toxic metals under the presence of excess levels of 
divalent or trivalent cations leading to the mobilization of calcium and metals from  
bone and deposition of these elements in nervous tissue (Yase 1996). No difference in 
muscle metal concentrations has been found between ALS patients and controls 
(Pierce-Ruhland and Patten 1980)  
  
Body fluids: Elevated concentrations of Al was found in CSF in ALS patients compared 
to controls (Sood et al. 1990). Plasma Cd levels were significantly (p=.005) raised in 
ALS cases compared to controls but with considerable overlap between groups 
(Pamphlett et al. 2001). Blood Cd concentrations were elevated compared to controls in 
an Italian study (Vinceti et al. 1997). Lower Co concentrations in ALS CSF but no 
other deviations was found in astudy of 20 patients and controls (Mitchell et al. 1984), 
that study however did not include metals with known neurotoxicity. 
 
Case reports: Observations on occupational metal exposure preceding ALS exist, as 
well as other specific and varied circumstances where exposure to metals with 
neurotoxic properties have preceded ALS onset. A 44-year-old ALS patient died after 9 
years of heavy exposure to Cd in a nickel-cadmium battery factory (Bar-Sela et al. 
2001). An Algerian woman was diagnosed with ALS after repeated respiratory 
exposure to Pb fumes from melting Pb (Bachmeyer et al. 2012). A Korean electronic 
parts manufacturing worker exposed to Pb (Oh et al. 2007) and other metals, with 
blood Pb concentration 31μg/dL half a year after ceased exposure, developed 
fasciculations, weakness and muscle atrophy diagnosed as ALS. Of special interest is 
an old report of bulbar ALS following Mn intoxication  (Voss 1939). Other case reports 
describing ALS following various Mn exposures to such as Mn mining or welding have 
been published (summarized in (Bowman et al. 2011)). Several other case reports with 
suspected or verified exposure to other metals preceding ALS symptoms can also be 
extracted (Adams et al. 1983, Hyser et al. 1987, Kantarjian 1961, Tanndag 1995). 
 
Systematic studies: In a series of 74 cases of ALS 15% had a history of extensive 
exposure to Pb compared with 5.4% of a control group. Previous fractures or skeleton 
disease was noted in 25% of patients compared with 9.4% of controls and the authors 
speculate in a relationship between ALS and skeletal demineralization. Bone biopsy Pb 
content was not elevated in these patients (Campbell et al. 1970). Another series of 74 
cases of ALS from the Mayo clinic were compared to 201 matched controls and a 
greater (p˂.05) exposure to Pb was found in the ALS group (Armon et al. 1991). 
Occupational exposure to Pb was significantly (OR=5.7) more common in ALS 
patients than in controls in a Scottish study (Chancellor et al. 1993). In a series of 31 
ALS cases it was found that 24out of those 31 had a history of metal exposure 
preceeding initial symptoms of ALS (Currier and Haerer 1968) . Several other studies 
report connections between metal exposure and ALS (Chio et al. 1991, Johnson and 
Atchison 2009). 
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2.4 PROTECTIVE MECHANISMS 
Some metals have been linked to ALS pathogenesis (Guidetti et al. 1996, Sutedja et 
al. 2009, Yase 1972). Metals are transported by metal binding proteins found in 
tissue, plasma and cerebrospinal fluid (CSF). These proteins have high affinity to 
toxic metals notably Cd, lead (Pb) and mercury (Hg). Other metal ions are part of the 
structure in many proteins. Some metal binding proteins, such as metallothionein 
(MT), are capable of storage, transport and exchange of several different metal ions. 
MT is a small protein with key functions in moderation of metal ion turnover and in 
metal detoxification. Some studies point towards an altered MT function in ALS 
(Aschner 1997, Gong and Elliott 2000, Hozumi et al. 2008, Sillevis Smitt et al. 1992, 
Sillevis Smitt et al. 1994). Metallothionein synthesis can be induced by Cd and other 
metals (Nordberg 1989). 
 
Metal contamination of soil, water and air is a growing problem of global magnitude. 
Uptake into living organisms and accumulation in food chains especially from marine 
animals is well described (Stoltenberg et al. 2003). The nervous system is partially 
protected from this exposure by barrier systems known as the blood-brain-barrier and 
the blood-liquor-barrier (Aschner and Aschner 1990, Aschner et al. 1999, Dobson et 
al. 2004, Zheng et al. 2003). However in situations of impaired barriers, or overload 
of metal, significant concentrations of metal can build up within the nervous system. 
To what extent these metal concentrations are reflected in the concentrations of the 
CSF is less known. Few reliable data exist on metals in CSF in humans (Basun et al. 
1994, Sjögren et al. 1996). Blood plasma levels of metals are more extensively 
studied and reference values exist for some metals (Nordberg et al. 1992).  
 
 
2.4.1 Barriers 
In the study of this thesis metal concentrations were studied in CSF, one out of four 
major fluid compartments of the brain. The other compartments are the blood that 
follows the arterial tree into the brain and perfuses brain cells and return through large 
vein sinuses to the heart, the interstitial fluid (ISF) that surrounds glial cells and 
neurons of the brain, and the intracellular fluid within those cells. There are no barriers 
between CSF and ISF and substances detected in the CSF are in equilibrium with the 
liquid compartment surrounding the nerve cells. However these two compartments are 
protected from the circulating blood by tightly connected endothelial cells in the blood 
vessels, constituting the BBB (Abbott et al. 2010). In addition to the well-studied BBB 
a second barrier system, known as the blood-CSF- barrier (BCSFB), anatomically 
represented by the choroid plexus (CP), is separating the CSF from the systemic 
circulation. The lateral ventricles, the third and the fourth ventricle are filled with 
choroid plexus structures and the CSF is secreted at high rate through the large villous 
surface of the choroid plexus. The CSF can be considered an ultrafiltrate of the blood. 
 
Chemical protection of the brain and spinal cord depends on the integrity of these two 
barrier systems, the BBB and the BCSFB. CNS homeostasis is closely regulated by the 
BCSFB . Transport of metals across brain barrier systems has been investigated in 
detail and specific protein transporters exist (Zheng et al. 2003), some of them 
unidirectional allowing metals to enter the CSF/ISF using inward directed transport 
mechanisms allowing for accumulation of metals inside of the barriers. The possibility 
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of metals with neurotoxic properties to selectively injure the barrier structure 
themselves (Shi and Zheng 2007) must also be taken into consideration.  
 
 
2.4.2 Metallothionein 
Metals form strong covalent bonds with sulphur (S). Amino acids rich in S are cysteine 
and methionine both found in high numbers in the small protein metallothionein (MT). 
The typical MT consists of 20 cysteines (30%), methionine, alanine, no aromatic amino 
acids, no histidine and it has a unique amino acid sequence with a tertiary structure 
forming two domains of metal clusters (Nordberg 2009).  Metallothionein synthesis is 
induced by metals, notably Cd and Zn. In some pioneering studies (Nordberg et al. 
1972) MT was isolated from rabbit liver after repeated Cd injections and two major 
forms of the protein could be characterized using isoelectric focusing. MT is mainly 
present in the cytoplasm of cells and exists in four major isoforms MT1– MT4. The 
isoform MT-3 is found in the nervous system. The human gene coding for MT is 
localized on chromosome 16 and MT proteins are small (6-7kDalton) typically binding 
7 metal ions. 
 
Metallothioneins have several functions in the metabolism and kinetics of metals. They 
have a unique metal binding capacity due to their stereochemistry and high content of 
sulphur rich cystein residues. Metallothioneins transport metal ions and is the major 
protein component in detoxification of neurotoxic metal ions and thus MTs protect 
neural tissues from metal toxicity. They are also free radical scavengers and store metal 
ions. Metallothioneins seem to have a role in neuroprotection. After injury to the central 
nervous system MT expression in astrocytes is highly elevated and neuroregenerative 
properties of MT are also described  (West et al. 2008). Motor neurons however do not 
express MT. A selective vulnerability of anterior horn cells to metals can be suspected. 
 
The spinal cord, degenerating in ALS, in thus protected from metals with toxic 
properties in several ways; Protected chemically by the astrocyte MT and other 
metalloproteins binding and regulating metal turnover, and protected by the 
compartments defined by the BBB and BCSFB that keep noxious substances outside of 
the endothelial lining of the central nervous system. The cord is also protected 
physically by the three meningeal coverings inside the vertebrae of the spine providing 
mechanical protection. Yet the anterior horns of the spinal cord degenerate in ALS. 
 
Direct sampling of CSF is possible by inserting a needle between the spinal processes 
of two lumbar vertebrae into the subarachnoidal space and collecting CSF that 
surrounds the spinal cord in equilibrium with extracellular fluid of the nerve cells. 
Simultaneous sampling from inside and outside of the barrier systems can yield 
information about barrier properties. 
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3 THIS STUDY 
ALS seems to present, as described in the background section, as a progressive disorder 
primarily affecting motor neurons of the spinal cord, with slowly increasing incidence 
worldwide, affecting several organ systems, and also found in animals. It is an always 
lethal degenerative disorder of the nervous system. In spite of more than a century of 
scientific effort the cause of this degeneration is still unknown. Observational data point 
in the direction of a multifactorial disease where there is support for environmental 
factors contributing and metals are candidate agents. Selective vulnerability in certain 
occupations and geoclustering of ALS further support this view. Several case reports, 
animal studies, exposure studies and systematic studies show elevated metal 
concentrations in ALS fluids and tissues.  
 
 
3.1 HYPOTHESIS AND AIMS 
This thesis project hypothesizes that neurotoxic metals contribute significantly to the 
pathogenesis of ALS and the overall aim of this thesis is therefore to characterize the 
relationship between metal exposure and ALS pathogenesis with a focus on metal 
concentrations in body fluids and barrier permeability to metals. 
 
To meet the overall project objective an integrated approach is taken to benefit from 
scientific knowledge and expertise in the fields of environmental medicine, clinical 
neurophysiology and neurology, as well as geology and inorganic chemistry.  
 
The specific aims of the thesis project were: 
 
 To investigate the electrophysiological and clinical properties of a member of 
the familial ALS subgroup carrying the H46R SOD1 mutation (Paper I). 
 
 To assess if cytokine concentrations are elevated in ALS CSF (Paper II). 
 
 To study in retrospect if mercury inhaled as vapour can reach the motor nuclei 
and anterior horn cells of the spinal cord in a primate (Paper III). 
 
 To develop sensitive laboratory analysis methods for the study of body fluids 
where metal concentrations are very low, specifically metals in CSF protein 
fractions separated by SEC-HPLC (Paper IV). 
 
 To study barrier properties by measurement of Mn concentrations in 
simultaneously drawn CSF and blood plasma samples (Paper V). 
 
 To investigate if metal toxicity contributes to ALS pathogeneses (Paper VI) 
This aim was digested into the following tasks: 
o To measure concentrations of metals in samples of CSF and blood 
plasma from ALS patients and compare with controls.  
o To correlate multiple metal concentrations in CSF to corresponding 
concentrations in plasma in order to assess possible accumulations. 
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3.2 MATERIAL AND METHODS 
Metal concentrations in CSF and blood plasma were measured with a sensitive 
technique suitable for multimetal studies and results from ALS patients were compared 
to control individuals without the disease. 
 
 
3.2.1 Ethical approvals 
Ethical approval for the research presented in this thesis was given by the local ethics 
committee (KI forskningskommitte´ Nord) in Stockholm Sweden (03-353) and the 
National Committee for Research Ethics (REK sør øst) in Olso Norway (470-03140). 
 
 
3.2.2 Study design 
Consecutive patients referred for electrophysiological investigation under the suspicion 
of ALS were recruited into a case control study (Figure 7). The setting was the 
laboratory of Clinical Neurophysiology at the Department of Neurology Oslo 
university hospital. Electrophysiological investigations (Higashihara and Sonoo 2007)  
were performed and differential diagnostic alternatives (see 1.3.2) were ruled out. The 
diagnosis of ALS was made independently by two neurologists with experience of the 
disease. 
 
Patients included met  El Escorial World Federation of Neurology criteria for the 
diagnosis of ALS (Brooks 1994) as revised by the 1998 Airlie House consensus group 
(Brooks et al. 2000b). These diagnostic criteria are restrictive and take into account 
both clinical and neurophysiological aspects of diagnosis. In recent years these criteria 
have been further developed putting even more emphasis on electrodiagnostic findings 
(de Carvalho et al. 2008). 
 
 
3.2.3 Sampling 
From each individual CSF was extracted. A Spirocan Quincke cut 0.9 mm needle was 
used. The first few drops were discarded and CSF collected in polypropylene tubes 
with lid and gasket and rinsed with ultra-pure water. Blood was drawn from an 
antecubital vein and centrifuged at 3000 rpm for 10 minutes and plasma removed with 
a clean plastic pipette to rinsed polypropylene tubes. All samples were frozen in two 
steps first to minus 20 
◦
C and then deep frozen to minus 86 
◦
C before metal analysis 
with HR-ICP-MS. Precautions were taken to avoid contamination of samples. 
Operation theatre cleanliness routines were applied to the sampling room, the patient 
was thoroughly washed, no gloves were used but surgical handwash and time from lid 
open to lid closed minimized. However no room air filtering was applied. As far as 
practically possible the international standard (Vesterberg et al. 1993) trace element 
measurements criteria and procedures (TRACY) were adhered to. 
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3.2.4 Clinical procedures 
Quantitative electromyographic studies were performed twice and showed positive 
sharp waves as well as fibrillation potentials indicating denervation (Higashihara and 
Sonoo 2007) in a pattern consistent with the diagnosis of ALS in each included case. 
Every patient was investigated clinically at separate occasions independently by two 
experienced neurologists before final diagnosis. Each patient was followed for two 
years or more to ensure clinical progression. Nerve conduction studies were performed 
to exclude other causes of denervation e.g. polyneuropathy. Seventeen ALS cases and 
10 controls were recruited. Friends or spouses of ALS patients, medical students or 
outpatients at the neurological clinic with minor complaints served as controls. 
Transient headache or numbness or worries for serious illness were considered minor. 
Controls were followed for at least two years for unexpected exacerbations and no such 
events occurred.  
 
 
3.2.5 Metal analysis 
HR-ICP-MS analyses were performed using a Thermo Finnigan model Element 2 
instrument (Germany). The radio frequency power was set at 1400W. The samples 
were introduced using a CETACASX 500 autosampler with a peristaltic pump 
(1ml/min). The instrument was equipped with a concentric Meinhart nebulizer 
connected to a Scott PFA spray chamber, platinum skimmer and interface cones and a 
quartz burner with a guard electrode. The nebulizer argon gas flow rate was adjusted to 
give a stable signal with maximum intensity for the nuclides 7Li, 115In and 238U. 
Methane gas was used to minimise interferences from carbon and to provide enhanced 
sensitivity (Rodushkin 2005). The instrument was calibrated using 0.6 M HNO3 
solutions of matrix matched multielement standards. Calibration curves using 5 
different concentrations were made using these standards. To check for instrumental 
drift, one of these multielement standards with known metal concentrations was 
Figure 7.  Flow chart of recruitment and sampling of CSF and blood plasma 
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analysed for every 10 samples. Certified reference material (SPS-SW1, SPS-SW-2, 
Spectrapure, Norway) were analysed at the beginning and end of each analytical 
sequence. Metals analysed were Metals analysed were Cd, Mo, Sn, Au, Hg, Pb, U, Mg, 
Al, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Rb, Sr, Ag,As and Se. 
 
3.2.6 Protein analysis 
A size exclusion column, Superdex 75, and HPLC system with quaternary pump, 
degasser, manual injector (100 μl loop) and a UV-detector (254 nm) was used for the 
separation of proteins in the CSF samples. Pump speed was set at 0.750 ml/min, and 
0.02 M Tris buffer with pH adjusted to 7.4 with 65% HNO3 was used as the mobile 
phase. Fractions (1 min per fraction) were collected in 5 ml sterile tubes using a 
fraction collector. The CSF samples were injected directly and untreated into the HPLC 
equipment. Before the first sample each day and between each sample the column was 
washed with at least 2 volumes of the mobile phase. The Superdex column was 
calibrated using proteins with known molecular weights ranging from 6 to 66 kDa. 
Insulin from bovine pancreas (MW=5.8 kDa, I5500, Sigma), lysozyme from chicken 
egg white (MW=14 kDa), trypsin inhibitor (MW=24 kDa) and albumin (MW=66 kDa) 
was used. To calibrate the column for MT, freeze dried liver MT (4.8 mg, MT-1 + MT-
2, MW = 7 kDa) had been prepared from rabbit liver (Nordberg et al. 1972), and 
dissolved in Tris (0.02M, 1 ml, pH 7.4) to a final concentration of 0.24 mg/ml.This 
concentration gave a narrow and defined double peak at 15 min elution time. The 
double peak is probably due to a partial overlap of MT-1 and MT-2. Fractions were 
subsequently analysed by “off-line” HR-ICP-MS for Cd, Cu, Fe, Mn and Zn. 
Reproducibility of the chromatography separations was checked by comparing repeated 
runs of the same sample. 
 
3.2.7 Statistical analysis 
The median test was used to evaluate if the median concentration of metals in CSF and 
plasma differed between ALS patients and controls. Due to the right tail distribution of 
the outcome variables, the difference in metal concentrations between ALS and 
controls was evaluated by the percentage of observations above the overall median 
(OM). By adding all values for ALS cases to all values for controls and finding the 
median value among the total, the OM was calculated. As the median is insensitive to 
outliers (Siegel.S. 1988), observations with very high concentration, as present in this 
material, do not yield misleading results when evaluated by the median test. Multiple 
comparison corrections were not applied. Confidence intervals of 95 % and hypothesis 
tests for the difference in proportion above OM between the groups was carried out 
using an exact version of the score statistic with a single two-sided inversion (Agresti 
and Min 2001). Nonparametric statistics were thus used to rank each metal according to 
its ability to separate the ALS patient group from the control group. The OM value was 
calculated for each metal, and the deviation from that median was expressed in percent 
units and used to describe the separation of the ALS group from the control group. 
Each metal was tested against the null hypothesis that the median was the same across 
the categories “ALS” or “control” using the independent samples median test. The null 
hypothesis was rejected when an exact significance <0.05 was reached. When rejected, 
the test was considered statistically significant. Graphs were prepared and analyses 
performed using the IBM SPSS statistics software. 
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3.3 RESULTS 
A case of verified familial ALS with a CuZn SOD 1 point mutation is presented in 
Paper I where the specific phenotype of this mutation, with preserved arm strength, is 
described. Concentrations of a set of cytokines were measured in ALS CSF and 
cytokines were not detected, as detailed in Paper II. Archive material from animal 
exposure experiments was studied with respect to the nervous system and 
accumulations of Hg in the spinal cord and motor nuclei of a primate were seen after 
inhalation of Hg. A selective vulnerability of anterior horn cells to metal toxicity could 
be suspected from these and other data (Paper III). Procedures to study the protein 
binding pattern of metals in CSF were developed. Proteins in CSF samples were 
separated by size exclusion chromatography combined with high performance liquid 
chromatography (SEC-HPLC). Fractions were then analysed for trace elements using 
high resolution inductively coupled plasma mass spectrometry (HR-ICP-MS). We were 
able to perform accurate multielement measurements of small samples of biological 
material with low concentrations of trace elements, near the detection limits (Paper 
IV). Manganese was found to be significantly elevated in ALS CSF compared to 
controls and conclusions on barrier properties supporting an inward transport of Mn 
could be drawn (Paper V). In CSF and blood plasma from ALS patients and controls 
22 metals were analysed and statistically significantly higher concentrations of Mn, Al, 
Cd, Co, Cu, Zn, Pb, V and U in CSF from ALS patients was found when compared to 
CSF from controls (Paper VI).  
 
 
3.3.1 Familial ALS (Paper I) 
Some 10% of ALS cases carry variants of known mutations in the Cu and Zn 
dependent superoxide dismutase protein (CuZn SOD1) genetically located at the long 
arm of chromosome 21. This familial ALS subgroup is in focus of intense research. A 
family with CuZn SOD 1 point mutation in exon 2 position 46, where histidine is 
substituted with arginine, was studied. The patients in this family present a 
characteristic phenotype with wasting of anterior tibial muscles bilaterally however 
preserved arm strength and slow progression of the disease. Time to respiratory 
failure can be more than 10 years in these cases and SOD sequencing can guide in 
prognostic evaluation. In summary Paper I describes the clinical presentation of a 
case of familial ALS.   
 
 
3.3.2 Cytokine profile in ALS CSF (Paper II) 
Cytokines are inflammatory markers and inflammation is seen in ALS. 
Neuroinflammation in ALS includes IgG deposits and infiltration of T-cells. The 
phenotype of intrathecal T-cells in ALS by multiplexed measurement of Th1 and Th2 
cytokines in CSF and supernatants of T-cell clones derived from CSF and blood were 
studied. Concentrations of IFN-c, TNF-a, IL-2, IL-4, IL-5 and IL-10 in CSF from ALS 
patients were below detection threshold of a sensitive multiplexed cytometric bead 
array. T-cell clones from CSF of an ALS patient displayed inferior proliferative 
capacity compared to T-cell clones from blood. The CSF clones could be induced to 
synthesize both Th1 and Th2 cytokines as well as IL-10. In summary Paper II shows 
that no T-cell cytokines could be found in ALS CSF. 
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3.3.3 Mercury in the spinal cord after inhalation of mercury (Paper III) 
Anterior horn cells of the spinal cord degenerate in ALS. Despite recent findings of 
more widespread affections in ALS, such as frontal lobe involvement and maybe subtle  
sensory impairment, the hallmark of the disease is degeneration of anterior horn cells in 
the spinal cord (Hughes 1982). Low dose long time exposure to metals (Crinnion 2000) 
is a possible cause of anterior horn cell degeneration. However it has been unclear if 
inhaled metal actually can reach the well protected anterior horn cells of the spinal 
cord, and if so contribute to degeneration of those cells.  
 
This investigation (Paper III) is an attempt to answer that question. It is a 
reinvestigation, with new emphasis on the spinal cord, of some classical respiratory 
metal exposure experiments in a primate, performed in 1984. Small marmoset monkeys 
(Callithrix jacchus) were exposed to 
203
Hg
0 vapour
 mixed into the breathing air in a 
concentration of 4-5 μg/liter. After one hour of exposure the monkeys were sacrificed 
and whole body auroradiograms prepared to study the distribution of Hg within organs. 
Uneven and specific distribution of Hg to the lung, liver and endocrine glands was 
noted. We performed in retrospect a detailed study of the nervous system of the 
monkey and found depositions of Hg inside of the spinal cord (Figure 8). Areas of 
enhanced accumulation anatomically corresponding to motor nuclei could also be 
observed.  
 
 
 
 
 
 
 
Similar experiments with respiratory Hg
vapour 
exposure have been performed in rodents 
(see section 2.2.2) also showing accumulation of the metal in anterior horn cells of the 
spinal cord. It may be hazardous to draw generalized conclusions from rodents into the 
human situation. However, data from primates are scarce, and the present investigation 
represents the only controlled radio-labelled Hg respiratory exposure experiment 
Figure 8. Mercury deposition in spinal cord and brain of Marmoset monkey following 
respiratory exposure to metallic Hg vapour. To the left the schematic drawing shows 
regions of Hg accumulation, represented by black dotted areas, in spinal cord and brain 
of exposed monkey. To the right Hg accumulations in motor nuclei are shown (black 
dots) and compared to original autoradiogram (red arrows). 
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performed in a primate where the distribution of Hg in the spinal cord is visualized. A 
comparison with results of rodent experiments is included in Paper III and it can be 
summarized that in the exposed rat granular deposits corresponding to the presence of 
inorganic Hg were found in the cytoplasm of rat ventral horn motor neurons. Thus 
inhaled Hg is deposited in the spinal cord of both rodent and primate, and that 
conclusion can be transferred to human beings too, although such experiments can no 
longer be performed for ethical reasons. The Hg accumulation seems to be localized to 
motor nuclei in the monkey (Paper III). In the mouse or rat, where more detailed 
localization is possible (Figure 6), Hg is found in the cytoplasm of anterior horn cells 
(Pamphlett and Waley 1996, Schionning et al. 1993b, Stankovic 2006, Su et al. 1998).  
 
In summary Paper III shows that unprotected anterior horn cells in the spinal cord of 
primates and rodents accumulate Hg after respiratory exposure. 
 
3.3.4 Separation of proteins and measurement of metal concentrations 
with HR-ICP-MS (Paper IV) 
A method to study the protein binding patterns of trace elements in human CSF was 
developed. Using size exclusion chromatography combined with high performance 
liquid chromatography (SEC-HPLC), proteins in CSF-samples were separated 
according to size. Fractions were collected every minute and each fraction was then 
analysed off-line using high resolution inductively coupled mass spectrometry (HR-
ICP-MS) to determine the concentrations of the trace elements in the fractions. 
Metallothionein separated into two distinct peaks (Figure 9) corresponding to the 
isoforms MT-1 and MT-2.  
 
 
 
 
 
 
Metal concentration profiles for zinc (Zn) and Cd showed peaks at approximately 15-
18 minutes, corresponding to expected retention time for MT (Figure 10). A high 
similarity between the profiles of these two metals, known to bind to MT, was 
achieved. The method was reproducible over time.  
 
Figure 9. Elution profile of metallothionein by HPLC. Light absorbance at 254nm 
on the ordinate and time in minutes on the abscissa. A double peak 
corresponding to MT-1 and MT-2 is seen.  
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The concentrations of many metals in human CSF are close to the detection limits, a 
fact that may be responsible for the scarce reports in the literature of CSF metal 
concentrations. The separation technique developed together with HR-ICP-MS analysis 
can be used to study metal containing proteins in body fluids also when metal 
concentrations are very low, which is the case especially after fractionation of CSF by 
HPLC, which inevitably entails a pronounced dilution. The technique is particularly 
useful for multielement analysis of small samples of biological material with low 
concentrations of trace elements. 
 
The eluents of the HPLC have to be tolerated by the plasma and the inlet system of the 
mass spectrometer, and high organic solvent concentrations or high salt concentrations 
cannot be used (Prange and Schaumloffel 2002). SEC-HPLC uses a non-denaturating 
mobile phase at physiological pH such as the TRIS-buffer, which stabilizes the original 
metalloprotein complexes and is easily tolerated by the HR-ICP-MS system (Prange 
and Schaumloffel 2002). No sample preconcentration is needed using this method. 
 
CSF metal concentrations for 8 individuals without neurological disorder were 
determined using the described methods. In summary Paper IV describes sensitive 
methods for protein separation and metal analysis in CSF and blood samples. 
 
3.3.5 Manganese in CSF and plasma from ALS patients (Paper V)  
Manganese is ubiquitous in soil, air, water and food. It is necessary for proper nerve 
cell function in low concentrations, but in higher concentrations neurotoxic. Food is the 
major source of intake and Mn homeostasis is regulated by hepatic excretion. 
Neurotoxic properties of Mn are well described (Milatovic et al. 2009) . Manganese 
crosses the BBB and accumulates in the central nervous system with longer half-life 
within nervous tissue. These known properties of Mn make this metal an interesting 
candidate for possibly causing the nerve cell degeneration in ALS. In this study Mn 
was analyzed in CSF and blood plasma from ALS patients and controls. Manganese 
concentrations were determined by the methods described in Paper IV. 
 
Manganese concentrations were found to be significantly higher in ALS CSF (median 
5.67 μg/L) than in CSF from controls (median 2.08 μg/L) (Figure 11). Also ALS CSF 
Mn concentrations were higher than ALS plasma Mn concentrations (median 0.91 
μg/L) suggesting transport of Mn into the central nervous system. CSF/plasma ratios 
were twice as high in ALS patients as in controls. 
Figure 10.  Zinc and Cd concentrations measured by HR-ICP-MS in fractions 
obtained by using HPLC with Superdex 75 and highly purified metallothionein. 
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Manganese transport mechanisms across the BBB are complex and seem to involve 
several proteins such as the divalent metal transporter-1; transferrin receptor; choline 
transporter; purinoceptors and other possible proteins (Fitsanakis et al. 2007) regulating 
Mn concentration in the CSF. Excess Mn in blood can lead to loss of regulation across 
the membrane and trapping of Mn in the CSF. The blood-CSF barrier may act as a lock 
allowing gradients to build up across the membrane and thus causing Mn to concentrate 
over time inside the CSF compartment in ALS patients. Dose dependent accumulation 
of Mn across brain regions has been shown in animal studies (Erikson et al. 2008) . 
Such an accumulation in humans may contribute to the relentless course of ALS. An 
autopsy study using neutron activation analysis on cross-sections of ALS spinal cords 
has shown elevated Mn concentrations in the anterior horns; most prominent in cervical 
regions (Miyata et al. 1983). 
 
In summary Paper V describes findings of elevated Mn concentrations in CSF from 
patients with ALS. 
 
 
3.3.6 Metals in CSF and plasma from ALS patients (Paper VI) 
In this study we wanted to make an unbiased evaluation of all possible and measureable 
metals in CSF and blood plasma from patients with ALS and controls. We studied 22 
metals, with and without known neurotoxicity, and analysed metal concentrations in 
CSF and blood plasma in a well-defined cohort of ALS patients diagnosed with 
quantitative electromyography (QEMG). Measurements were performed with the 
methods described in Paper IV, well suited for simultaneous measurements of many 
metals in low concentrations. Statistics based on the median concentration value for 
each metal was performed and results are shown as level of deviation from the overall 
median (Figure 12). 
 
 
 
Figure 11. Boxplots showing median concentrations of Mn in CSF and blood plasma 
from ALS patients and controls. The whiskers represent the 25th and 75th percentiles, 
circles represents outliers in the 1.5* interquartile range.   
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Significantly elevated metal concentrations were found in CSF from ALS patients 
compared to controls for the metals Mn, Al, Cd, Co, Cu, Zn, Pb, V and U. The 
concentrations of these nine metals in blood plasma were lower than in CSF indicating 
the existence of inward directed transport mechanisms across the BBB. Several metals 
with known neurotoxicity were thus found in CSF from patients with ALS. 
 
The ALS cases with the highest CSF concentrations of a metal with neurotoxic 
properties also demonstrated high concentrations of other neurotoxic metals (Table 3). 
Raw data metal concentrations can be found in the Supplementary material to Paper 
VI. 
 
In summary Paper VI describes findings of several neurotoxic metals in statistically 
significantly elevated concentrations in CSF from ALS patients compared to controls.  
Patterns of CSF metal coexistence are recognized and possible synergisms are 
discussed. 
 
 
 
 
 
 
Figure 12. Proportion of CSF metal concentration measurements that fall above the 
combined median value (overall median) for both ALS case values and control values. 
Individual metals are reported from top to bottom in order of increasing ability to 
discriminate between groups. Length of bar represents percentage units with 100% 
(1.00) as maximum 
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3.4 DISCUSSION 
The primary objective of this thesis was to characterize the relationship between metal 
exposure and ALS pathogenesis. Furthermore I intended to measure metal 
concentrations in CSF and plasma from ALS patients. Below the findings are discussed 
in relation to previous research findings in the field of neurodegeneration and a model 
for ALS pathogenesis is suggested. 
 
 
3.4.1 Familial ALS patients show specific phenotypes 
A patient carrying the H46R SOD1 mutation presents with slowly progressing paresis 
of the lower limbs has preserved arm strength and a favourable prognosis (Paper I). 
His large family shows the same phenotype and can be suspected to carry the same 
mutation. This is the first report of this aberration in a patient of Pakistanian descent. It 
adds to the descriptions of more than 100 different mutations found in familial ALS. It 
is important to find these families as survival time is sometimes protracted, as in this 
case, and symptom distribution specific to the different SOD mutation varieties. Cases 
of hereditary ALS can be attributed to mutations in several different genes, the most 
common being SOD. These identified genes explain about 30% of the cases of familial 
ALS, but not the remaining ones (Andersen and Al-Chalabi 2011). 
Table 3. Distribution of metals in CSF from ALS cases (n=17) and controls (n=10). A 
concentration one standard deviation (1SD) or more above the mean for the combined 
cases and controls for that metal is indicated by a small circle (◦). Metals with known 
neurotoxic properties, also present in concentrations at or above 1SD, are marked with a 
larger triangle (▼). 
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3.4.2 Cytokines are not detected in ALS CSF 
No T-cell cytokines could be found in ALS CSF (PaperII). Inflammatory theories on 
ALS causation involve cytokines as possible mediators of inflammation. However 
efforts to quantify IFN-c or IL-12 in ALS CSF have so far been unsuccessful, in 
accordance with our finding of undetectable levels of several cytokines in ALS CSF. 
Are cytokines modifying the glial response in ALS?  The role of neuroinflammation in 
ALS in still evolving and specifically T-cell involvement is unclear as the T-cell can 
both protect and damage neurons and the influence of T-cells on protective properties 
of microglia is in research focus (Holmoy 2008). Metal accumulation (see below) in 
neurons as a prerequisite for inflammation is a possible scenario combining 
environmental and inflammatory theories in ALS. 
 
 
3.4.3 Inhaled mercury vapour penetrates protective barriers and can be 
detected in the spinal cord 
Mercury accumulation seems to be localized to motor nuclei in primates after 
respiratory Hg exposure (Paper III). The respiratory epithelium constitutes a large 
cellular surface vulnerable to exposure from airborne metal fumes, dust or vapour.  
Low dose long time exposure to metals through the respiratory pathway may lead to 
elevated concentrations in tissue. Such respiratory exposure can be anticipated to pass 
unnoticed, without acute symptoms, and accumulations can build over time. 
 
However an interesting question remains unanswered, crucial to a deeper understanding 
of the chemical conditions of the anterior horn cells of the motor system in the spinal 
cord: Is it at all possible for inhaled metal to reach the anterior horn cells of the spinal 
cord?  If so respiratory exposure needs to cause an increased concentration of metal in 
the alveolar air and then drive diffusion of metal over the combined alveolar and 
endothelial membranes elevating the metal concentration of peripheral blood 
contributing to widespread distribution of metal to different internal organs and tissues. 
In order to enter the central nervous system metal ions or atoms have to pass barrier 
systems either at the level of the choroid plexus bypassing the protective mechanisms 
of the plexus endothelium and then entering into the CSF, or at the level of the cerebral 
capillaries constituting the BBB entering directly into the cerebral interstitial fluid 
(Zheng et al. 2003). The possibility of injury by Hg to the protective capillary 
membranes themselves or to the choroid plexus must also be taken into consideration. 
Such injury to the choroid plexus has been demonstrated for Cd in mice where necrosis 
of the choroid plexus epithelial cells were observed following intermediate duration 
exposure to 1.4 mg Cd/kg/day as Cd chloride (Valois and Webster 1989) . Once inside 
the central nervous system and present and detectable in the CSF, metal has to pass the 
cellular membrane of the anterior horn cell itself and cause toxic degeneration. Are 
these series of events possible? 
 
Data from primates (Paper III) and rodents (Figure 6) thus indicate Hg accumulation 
in spinal cord motor nuclei after respiratory exposure. What properties of anterior horn 
cells contribute to metal accumulation specifically in those cells? Or what kind of 
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protection do other parts of the spinal cord benefit from, that the anterior horn cells are 
lacking? Distribution of metal in tissues depends on many factors such as route of 
exposure and chemical properties of metal as well as timing of dosage and 
concentration of dose. Thus dermal and intravenous routes cause a pattern of 
distribution different from what is found after respiratory exposure. It is also known 
(Berlin et al. 1969) that respiratory Hg exposure causes some tenfold higher tissue 
concentrations than  intravenous exposure. 
 
The granular Hg depositions are confined to the anterior horn cells exclusively and the 
surrounding astrocytes do not contain any metallic granulae (Figure 6) after respiratory 
Hg exposure. Protective mechanisms in astrocytes and other glial cells may prevent an 
accumulation of Hg outside of the anterior horn cells. Certain metalloproteins such as 
MT provide protection shown by the fact that MT induction in mouse cells in vitro is 
higher in astrocytes than in neurons (West et al. 2008). Metallothioneins have a 
protective effect upon nerve cells as MT knockout mice (Stankovic 2005) show more 
pronounced axon atrophy after Hg vapour exposure than do wild type mice. In Hg 
vapour exposed MT knockout mice (Stankovic et al. 2003) no MT expression was 
noted neither in the motor neurons of the spinal cord nor in the axons of the ventral 
root. Interestingly enough no MT expression in these structures was noted in the wild 
type mice either. Axons in the ventral root of wt mice did not stain for MT (Stankovic 
et al. 2003). The reactive astrocyte is known to express and induce MT but the anterior 
horn cell itself seems to be unprotected in situations of metal exposure. Taken together 
it seems possible that inhaled metal passes protective barriers and accumulates in 
anterior horn cells of the spinal cord, contributing to direct toxic effects involved in the 
degeneration of those cells. 
 
 
3.4.4 Metals detected in ALS CSF are neurotoxicants 
Increased concentrations were measured for the metal isotopes manganese (Mn
55
), 
aluminum (Al
27
), cadmium (Cd
111
) cobalt (Co
59
), copper (Cu
63
), zinc (Zn
66
), lead 
(Pb
208
), vanadium (V
51
) and uranium (U
238
) in CSF from patients with ALS compared 
to controls (Paper V+VI) (Figure 12). Using nonparametric statistics we noted that 
these nine metals showed statistically significant elevations from a total of 22 analyzed 
elements. Many of the found metals, but not all of them, can be described as 
neurotoxicants. 
 
In addition to these nine isotopes with significantly elevated concentrations, also 
mercury (Hg
200
) and arsenic (As
75
) may be discussed in the context of neurotoxicity. 
They were found in increased concentrations in ALS CSF however did not reach 
statistical significance in our study, as high levels of Hg and As also were found in 
some of the control individuals. 
 
From independent sources (Paper VI) information has been gathered evaluating the 
neurotoxic properties of all elements analyzed. From these established data the metals 
Al, Mn, As, Hg and Pb can be designated as neurotoxicants (Krewski et al. 2007, 
Milatovic et al. 2009, Monnet-Tschudi et al. 2006, Sanders et al. 2009, Vahidnia et al. 
2007). In addition to these metals also Cd (Michalke et al. 2009) and U (Aschner and 
 39 
 
Jiang 2009b, Jiang et al. 2009, Jiang et al. 2007) have been suggested in some studies to 
cause neurotoxicity. 
 
Thus 5 out of 9 found metals found in statistically elevated concentrations are 
established neurotoxicants or suggested to cause neurotoxicity, and 2 metals found in 
elevated concentrations albeit not significantly elevated are neurotoxicants. In summary 
metals with neurotoxic properties (Figure 13) were found in ALS CSF in our study. 
 
The ALS cases with the highest CSF concentrations of a metal with neurotoxic 
properties also demonstrated high concentrations of other metals with neurotoxic 
properties (Table 3). For example, the ALS patient with the highest CSF Pb 
concentration [ALS 200] concurrently demonstrated high concentrations of Al, Cd, Mn 
and U. The ALS patient with the second highest Cd concentration [ALS 422] was also 
second highest in Mn and simultaneously showed high concentrations 
of Al, As, Pb and U. A third example of this pattern of multiple occurrence in ALS 
CSF of metals with known neurotoxicity was the individual with the highest Cd 
concentration [ALS 734] who also showed high concentrations of Al, As, Hg and Mn. 
These patterns of multiple occurrences of high concentrations of metals with neurotoxic 
properties in the same patient were not present in the plasma samples where 
peak concentrations were more scattered.  
 
 
3.4.4.1 Individual metals and links to ALS-like symptoms  
 
Table 4. Proportion of ALS cases 
and controls with metal findings
1
 
Metal ALS Controls 
 % % 
Al 30 0 
V 12 0 
Mn 30 0 
Co 18 0 
Cu 30 0 
Zn 23 10 
Cd 35 0 
Pb 30 10 
U 47 0 
Hg* 18 20 
As* 24 20 
 
1
  ≥ 1SD above combined 
mean.Percent of total. See text for 
details.  *=NS 
 
For each metal the supportive literature data are summarized and discussed first in 
relation to effects on the nervous system and then, when available, in relation to ALS. 
 
In this section each metal showing 
statistically significantly elevated 
concentration in this study is discussed 
in more detail in relation to muscle 
atrophy and muscle weakness, the 
most prominent symptoms in ALS. 
Aluminium, V, Mn, Co, Cu, Zn, Cd, 
Pb and U were thus found (Paper VI) 
in CSF in a higher proportion in ALS 
cases than in controls, expressed here 
as % for each metal (Table 4). When 
indicated as found the concentration 
value in CSF was defined as above or 
at a cut-off limit set to one standard 
deviation (1SD) above the mean for 
the combined cases and controls for 
that metal (Figure 12). 
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Aluminum (Al) was in our study, using the 1SD criterion, found in CSF from 30% of 
ALS cases and not found in CSF from control individuals (Table 3). Al is a well-
known neurotoxicant. Encephalopathy from Al containing dialysis fluids is described 
and nervous system symptoms from Al medical procedures such as bone cement, 
intravenous feeding and irrigation of the urine bladder are described  (Flaten et al. 
1996). High Al concentrations are noted at autopsy in brains from AD patients 
(Crapper et al. 1973), but replication studies are inconsistent. Motor neuron 
degeneration has been shown in mice following Al hydroxide injections (Shaw and 
Petrik 2009). Motor neuron degeneration with neurofibrillary tangle formation, 
chromatolysis and abnormal localization of nuclei, resembling ALS pathology, is 
observed in mice after Al injection (Tanridag et al. 1999) and ALS-like skin changes 
have been observed in mice overfed with Al (Kihira et al. 2004). Monkeys recieving a 
diet low in calcium and high in Al developed ALS motor neuron pathology (Garruto et 
al. 1989). Elevated CSF Al concentrations have earlier been found in ALS and an ALS-
like syndrome due to Al intoxication has been described (Tanndag 1995). 
 
Vanadium (V) was, using the 1SD criterion found in CSF from 12% of cases and not 
found in controls. Inhalation of V caused changes in excitability of tibial musculature in 
rats. Acute V intoxication in experimental animals causes death preceded by paralysis 
of the hind legs. Vanadium exerts neurotoxic effects in dopaminergic neuronal cells 
(Afeseh Ngwa et al. 2009). 
 
Manganese (Mn) was, using the 1SD criterion, found in CSF from 30% of cases and 
not found in controls. All individuals showing Mn values above 1SD were ALS cases. 
Neurotoxic properties of Mn are well described (Dobson et al. 2004). Mn crosses BBB 
and accumulates in the central nervous system with longer half-life within nervous 
tissue. Cumulative mechanisms of neurotoxicity seem to cause manganism with 
progressive irreversible brain impairment. Similarities to Parkinson disease have been 
discussed (Aschner et al. 2009a). Muscle wasting leading to paraplegia as a result of 
respiratory exposure to Mn has also been described (Couper 1837). Welders exposed to 
Mn show dose-response related motor impairments (Sjögren et al. 1996), and impaired 
fine motor skills (Ellingsen et al. 2008). Manganese accumulation primarily in nuclei of 
cultured brain cells has been described (Kalia et al. 2008). Manganese also inhibits 
choline transport over the barrier systems via competitive mechanisms possibly 
contributing to neuronal degeneration. Manganese may enter the CNS through the 
choline transporter (Lockman et al. 2001). Elevated Mn concentrations are reported 
(Miyata et al. 1983) in spinal cord sections from ALS patients. Manganese 
concentrations were in our study significantly higher in ALS CSF (median 5.67 μg/L) 
than in CSF from controls (median 2.08 μg/L). Also ALS CSF Mn concentrations were 
higher than ALS plasma Mn concentrations (median 0.91 μg/L) suggesting transport of 
Mn into the central nervous system (Paper V). 
 
Cobalt (Co) was, using the 1SD criterion, found in CSF from 18% of cases and not 
found in controls. Cobalt exposure affects the respiratory system and haematopoiesis 
but no reports on human nervous system effects of Co have been published, however 
motor neuron like cell lines exposed to Co chloride showed signs of oxidative toxicity 
associated with motor neuron death in ALS (Xu et al. 2011). 
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Copper (Cu) was, using the 1SD criterion, found in CSF from 30% of cases and not 
found in controls. Cu concentrations are effectively regulated and mutations in 
regulatory proteins give Menkes disease and Wilson’s disease, both affecting the 
nervous system. Inorganic Cu, as found in drinking water and in vitamin supplements is 
potentially toxic to the brain, possibly contributing to AD development (Brewer 2012). 
One case of early onset ALS with elevated Cu levels has been described (Ibrahimagic 
et al. 2006). 
 
Zinc (Zn) was, using the 1SD criterion, found in CSF from 23% of cases and 10% of 
controls. Zinc is a metal essential for life; however excess intake of Zn impairs Cu 
availability, probably through MT-related mechanisms. Zn is necessary for brain 
development and function and is essential for nerve conduction. No ALS cases are 
associated with Zn deficiency or elevated Zn concentrations have been described but 
some hypotheses relate Zn deficiency to ALS (Smith and Lee 2007). 
 
Cadmium (Cd) was, using the 1SD criterion, found in CSF from 35% of cases and not 
found in controls. Cadmium is not part of any normal cellular processes and Cd is toxic 
at very low exposure levels (Nordberg et al. 2002). Cd exposure through tobacco 
smoking is a health concern. Cd is transported in plasma largely bound to 
metallothionein (Bachmeyer et al. 2012) and Cd stimulates MT synthesis (Nordberg et 
al. 1992). No difference in blood Cd levels between AD patients and controls could be 
found in a Swedish study (Basun et al. 1994). Cd concentrations were markedly and 
significantly elevated both in grey and white matter in formalin-fixed brain tissue from 
Guam ALS cases (Gellein et al. 2003). A patient diagnosed with ALS after nine years 
of Cd exposure in a Ni-Cd battery factory has been described (Bar-Sela et al. 2001). 
 
Lead (Pb) was, using the 1SD criterion, found in CSF from 30% of cases and 10% of 
controls. Exposure to Pb causes a motor neuropathy characterized by weakness and 
atrophy of skeletal muscles without sensory involvement. The spinal origin of this 
neuropathy following chronic low dose Pb intoxications has been debated for more 
than a century (Beritic 1989, Planches 1839, Preiskel 1958) and the historical 
observations from a series of 1213 Pb intoxicated patients stating the anterior horn of 
the spinal cord as the site of injury, are still valid (Planches 1839). In the original 
descriptions of ALS by Aran from 1850 he states that 3 of his 11 ALS patients had 
been in contact with Pb and 2 of them had a history of Pb poisoning (Aran 1850). 
Informations from early sources are necessary in evaluating long time low dose 
exposures to Pb as the most common exposures such as brass metal industry, manual 
paint removal work, Pb contaminated food or beverages, or even leaded gasoline, no 
longer exist. Worldwide however new challenges appear with the electronic industry 
contributing to a new increase in Pb exposure (Meyer et al. 2008), together with paint, 
leaded childrens toys, traditional remedies, smelting operations and battery recycling as 
main sources (Meyer et al. 2008). 
 
The Pb isolated motor neuropathy is similar to the clinical presentations in ALS and Pb 
is the metal that has been most intensely discussed over the decades as a possible 
causative agent in ALS. The similarities include pure motor engagement, often normal 
motor conduction velocities, occurrence of fibrillation potentials (Seppalainen and 
Hernberg 1972) and slow onset. The anterior horn cell involvement in Pb intoxication 
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is not contradicted by the fact that some investigators (Seppalainen and Hernberg 1972) 
find reduced motor conduction velocities in exposed patients, as axonal deterioration 
(of anterior horn cell origin or otherwise) and the concomitant reduction of motor 
amplitudes at a certain level of axonal destruction is followed by reductions in 
conduction velocities by the mechanism of the fastest axons dying first (Tankisi et al. 
2007). Slowing of nerve conduction velocities without findings of reduced motor 
amplitudes have not been recorded in Pb intoxication cases. The fibrillation potentials 
found in Pb intoxication subjects (Seppalainen and Hernberg 1972) may well indicate 
anterior horn cell involvement. To what extent reduced motor nerve conduction 
velocities should be used as a marker for early Pb exposure has been subject for critical 
review (Beritic 1984). Histological evidence indicate that segmental demyelination is 
not present in Pb intoxication (Buchthal and Behse 1979) and segmental demyelination 
is not observed in ALS. Reports of proven anterior horn cell involvement in definite Pb 
intoxications are scarce (Limonta and Capellini 1976) and further investigations using 
electrophysiological methods are needed to pinpoint such an involvement.  
 
A case report of proven Pb intoxication 12 years after a Pb bullet penetrated into an 
intervertebral space (Grogan and Bucholz 1981) describes a patient in a lethargic state 
with progressive profound muscle weakness. Muscle biopsy in this case showed 
atrophic muscle fibres consistent with neuropathic disease and the weakness of this 
patient evolved into widespread weakness in all muscles calling for tracheal intubation 
and ventilation support.  A 39-year-old factory worker handling Pb oxide showed 
atrophy, spasticity and fasciculations of lower extremities after excess Pb exposure and 
that patient subsequently died from ALS (Oh et al. 2007). Vesterberg used flameless 
atomic absorption spectrophotometry to measure Pb in blood plasma and found 
elevated concentrations in ALS patients compared to controls (Conradi et al. 1978). 
 
A recent large study conducted by the National Institute of Environmental Health 
Sciences (NIEHS) observed that blood Pb levels were higher among ALS cases 
compared with controls (p<0.0001, age adjusted) (Fang et al. 2010). Differences in 
bone turnover or polymorphism in Pb metabolism enzymes did not modify this distinct 
association. A Californian study of  165 ALS patients (Albers 2009) also found a 
statistically significant positive association between blood Pb levels and ALS, albeit not 
between bone Pb levels and ALS. Earlier studies have associated ALS risk with Pb 
elevations in blood and bone (Kamel et al. 2005, Kamel et al. 2002) and concluded 
with a potential role for Pb exposure in the etiology of ALS. An early study tried to 
identify events preceding the development of ALS and one such events was exposure to 
Pb (Felmus et al. 1976) . 
   
A small but significant ALS cluster has been identified next to a Pb smelter factory 
(Turabelidze et al. 2008). Of special interest is the epidemiological study conducted in 
possibly Pb contaminated districts in Italy (Guidetti et al. 1996) where elevated 
incidences of ALS were found in possibly Pb contaminated regions compared to 
neighbouring districts. 
 
Uranium (U) in CSF was, using the 1SD criterion, found in 47% of cases and not found 
in controls. Adverse health effects of U involve combined chemical and radiological 
mechanisms with chemical toxicity being most important (Morris et al. 1989). 
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Absorption of U is low regardless of exposure route and highly dependent on its 
solubility. Inhaled U dust particles of low solubility can be retained for years. The main 
target for U toxicity is the kidney where atrophy and necrosis of glomerular walls 
occur. Accumulation in rat brain after respiratory U exposure is heterogeneous with the 
higher concentrations in the olfactory bulbs and cerebellum (Houpert et al. 2007). Rats 
surgically implanted with U pellets showed after 6 months presence of U in the cortex, 
midbrain, and cerebellum suggesting that U preferentially accumulates in specific brain 
regions after exposure (Aschner and Jiang 2009b). Geochemical conditions in Sweden, 
having the same natural occurrence of U as Norway, imply elevated U in drinking 
water. Regulatory Agencies in Sweden have limited highest allowed concentration of U 
in drinking water to 15 microgram per litre (WHO 2004). Laboratory experiments 
(Aschner and Jiang 2009b) using organisms such as Caenorhabditis Elegans and rats 
have concluded with low acute neurotoxic potential of U following exposure and a 
protective potential from metallothionein. No connection between U and ALS has 
previously been reported. 
 
Also worth discussing although not significantly elevated compared to controls in our 
study (Paper VI) are the elements Hg and As. These two elements were elevated in 
ALS CSF but did not reach statistical significance as elevated concentrations were 
found also in control CSF. However there are a number of case reports or case series 
connecting both Hg and As to ALS and they are summarized here. 
 
Mercury (Hg) is widespread in the biosphere, both from natural and human sources 
such as combustion of fossil fuels and industrial release. Mercury occurs as elemental 
Hg and as Hg vapour, as Hg salts or Hg organic compounds all with different 
toxicological properties. Mercury has a long history of adverse reactions and the CNS 
is the critical organ for long-term exposure  (Nordberg et al. 2007a). Effects on foetal 
brain development, cognitive defects, brain atrophy and peripheral neuropathy are 
described (Nordberg et al. 2007a). Inhalation of Hg vapour can reach the spinal cord 
and seem to accumulate in anterior horn cells (Paper III). Several case reports or case 
series describe ALS development, often with a delay, after various forms of Hg 
exposure. 
 
Accidental injection of elemental Hg from a thermometer into the hand of a nurse 
resulted in an ALS syndrome with a delay of three years (Schwarz et al. 1996). A 
farmer noted progressive weakness in all extremities and widespread muscle atrophy, 
diagnosed as ALS, following respiratory exposure to ethylphenyl Hg. Post mortem 
examination of the spinal cord showed moderate frontal lobe atrophy and almost 
complete absence of anterior horn cells in the spinal cord (Brown 1954).  Eleven 
patients developed irreversible ALS after ingestion of ethylmercury-p-toluene 
sulfonanilide used as a fungicide for wheat flour used in bread (Kantarjian 1961). 
Another case of Hg exposure from collecting liquid Hg from thermometers was 
followed 3 months later by muscle twitching, weakness and muscle atrophy developing 
into an ALS-like syndrome confirmed by EMG (Adams et al. 1983). Two Hg oxide 
factory workers exposed to both Hg oxide and Hg vapour developed massive 
fasciculations, complaints of muscle weakness and symptoms and signs resembling 
those found in ALS (Barber 1978). An elderly woman developed progressive weakness 
of one hand developing into ALS after dermal and/or respiratory exposure to metallic 
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Hg (Praline et al. 2007). Diffuse denervation of all limbs including the tongue was 
confirmed by EMG. From regions in India with Hg contaminated stream water elevated 
Hg concentrations in blood from ALS patients have been described (Kumar et al. 2010)  
 
Arsenic (As) occurs in organic form in seafood and as inorganic As in water and 
beverages. As is readily absorbed after ingestion and widely distributed in the body. 
Inorganic As causes skin lesions and skin cancer and effects on heart, peripheral 
circulation and the nervous system have been reported (Nordberg et al. 2007a). Other 
effects of As intoxication are hyperpigmentation, various forms of cancer, sensory 
axonopathy, endocrine disruption and foetal loss. Chronic As toxicity has been 
described to cause hearing loss, mental retardation, encephalopathy and polyneuropathy 
(Nordberg et al. 2007a). 
 
To what extent As accumulates in the spinal cord is less studied, but ingestion of As 
causes widespread neurogenic muscle atrophy and weakness as illustrated by case 
reports (Greenberg et al. 1979, McCutchen and Utterback 1966, Stenehjem et al. 2007), 
some systematic studies (Heyman et al. 1956) and a review (Hall 2002) of the effects of 
chronic As exposure symptoms. This generalized atrophy and weakness in prolonged 
and slow and the motor symptoms of As intoxication are similar to the atrophy and 
weakness seen in ALS. The duration of exposure and dose seem to influence to what 
extent sensory or motor symptoms dominate and most reports describe end stages with 
widespread motor impairment. In a study of 41 cases of more or less chronic As 
exposure severe symmetrical muscular weakness of the extremities was an outstanding 
feature of the As poisoning. Twentyseven patients out of 41 showed foot-drop, 24 were 
unable to walk and 16 were unable to stand without assistance. Fasciculations were also 
noted in some of these cases (Heyman et al. 1956). A large study of long time low dose 
exposure from groundwater As contamination in India (Mukherjee et al. 2003) showed 
muscle atrophy and weakness in 7-10% of exposed individuals. A case of arsenicosis 
presenting with upper and lower motor neuron signs as in ALS has also been reported 
from India (Mazumdar et al. 2010). Two detailed reports of progressive muscle 
weakness of all limb muscles evolving into tetraparesis and respiratory failure due to 
extreme weakness of the respiratory muscles following As exposure are also published 
(Greenberg et al. 1979, Stenehjem et al. 2007). 
 
When considered separately the nine found metals (Al, V, Mn, Co, Cu, Zn, Cd, Pb and 
U) can in different ways be linked to aspects of ALS pathology as described for each 
metal above. The most likely offender is Pb, and Pb intoxications produce ALS-like 
states. Uranium concentrations are all over low, but the statistics are very convincing 
with all the higher concentrations among ALS cases. Aluminium, Mn and Cd with 
established neurotoxic properties are also possible candidates when ALS pathogenesis 
is evaluated. Combinations of metals should be considered (Table 5). 
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3.4.4.2 Combinations of metals and links to ALS 
Several metals with neurotoxic properties were found in CSF in the study of this thesis 
and combined toxicities may occur. In the clinical setting simultaneous exposure to 
multiple metals through the air, food and water can be expected. Different combined 
effect of the metals Al, V, Mn, Co, Cu, Zn, Cd, Pb and U should be sought for. Recent 
observations (Rai et al. 2011) on rat astrocytes show that a mixture of As, Cd, and Pb 
has the capacity to induce synergistic toxicity and may influence the BBB. 
 
The clinical variation seen in ALS may be due to the combined effects of these metals, 
accounting for variability in time of onset, rate of progression, variations in symptoms 
and time to death. Abortive cases of ALS are rare however a wide variation in disease 
duration is seen, ranging from a few months to a decade or more (Qureshi et al. 2009). 
Toxicity from one metal enhancing the toxic effects of another metal may account for 
such variation. 
 
Table 5. Summary of metals 
found in CSF from patients with 
ALS in statistically significantly 
elevated concentrations 
compared to controls (Paper 
VI). Metals present in 
concentrations 1SD or more 
above the mean for the 
combined cases and controls 
are marked with a small circle 
(◦). Metals with known 
neurotoxic properties, also 
present in concentrations at or 
above 1SD, are marked with a 
larger triangle (▼).  
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The metal most often suspected to be involved in ALS causation is Pb. However Pb 
alone seems to produce a syndrome somewhat different from ALS. Slow Pb 
intoxication is similar to ALS in many respects and in both conditions exclusively 
motor neurons are affected. Both show insidious onset and both are indolent. The 
atrophy and distribution of the distal paresis in Pb intoxication is clinically 
indistinguishable from ALS paresis (Beritic 1984). Lead intoxication may affect 
innervation to speech muscles in the same way as in ALS producing Pb induced 
dysarthria (Benetou-Marantidou et al. 1988). 
 
The level of motor nerve injury in slow Pb intoxication has been a controversy for two 
centuries (Beritic 1984) however it seems justified to settle a topical diagnosis of Pb 
intoxication to the anterior horn cells of the spinal cord , the same cells that are affected 
in ALS. Experimental findings (Yokoyama et al. 2000) confirm that anterior horn cells 
are selectively sensitive to Pb neurotoxicity. Reduced motor amplitudes, seen in both 
disorders, are a consequence of anterior horn cell degradation, and fibrillation potentials 
indicating denervation, are found in both (Seppalainen and Hernberg 1972). Preserved 
or almost preserved motor conduction velocities are found in slow Pb intoxication 
(Buchthal and Behse 1979) as well as in ALS incompatible with demyelination. 
Histology in sural nerve biopsies show no injury to myelin but axonal loss following Pb 
exposure (Buchthal and Behse 1979). 
 
However two distinct differences are important: A/ Recovery from slow Pb intoxication 
is possible (Beritic 1984), but ALS is always fatal.   B/ Colic and other symptoms 
(Beritic 1984, Ehle 1986) precede motor deterioration in slow Pb neuropathy, but 
muscle weakness and atrophy are first signs (Rosenfeld 2000) of ALS without any 
obvious preceding symptoms.  If slow Pb exposure contributes to ALS development 
why are these differences present? We have found elevated concentrations of Pb in 
CSF from patients with ALS (Paper VI). Early investigators (Conradi et al. 1976) 
noted elevated Pb levels in ALS CSF compared to controls, and follow up studies 
confirmed this difference (Conradi et al. 1978) (Conradi et al. 1980), however with 
overall lower concentrations. Methodological issues and the fact that the large Pb pool 
is found within erythrocytes may explain these variations. These researchers also noted 
an elevated erythrocyte fragility in ALS compared to controls when erythrocytes were 
incubated with Pb nitrate (Ronnevi et al. 1982). Those studies were performed on Pb 
only. Based on early findings and our measurements of many different metals in ALS 
CSF (Paper VI, Table 4) it seems reasonable to propose that synergistic effects 
between Pb and at least one more metal toxic to nerve cells are necessary for 
development of the clinical picture of muscle weakness and atrophy seen in ALS, 
including its variable presentation. 
 
Different routes of exposure may lead to accumulations in CSF of several neurotoxic 
metals including Pb. Synergistic effects can be anticipated. Considering the complex 
nature of environmental and occupational metal exposure in the industrial world it is 
less likely that one single element could be responsible for all the diverse types of tissue 
damage seen in ALS, both at the cellular level and at the ultrastructural level, nor in 
other neurodegenerative disorders. A multimetal exposure situation may more 
accurately describe the observed damage to nerve cells. Multi metal toxicity and 
synergistic effects can be suspected. An integrated view of the role of metals in the 
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pathogenesis of ALS and other disorders of the nervous system has been published 
(Roos et al. 2006). 
 
 
3.4.5 Protective proteins   
Exposure to metals with neurotoxic properties can be linked to symtoms of ALS. Motor 
neurons of the spinal cord are protected from these metals by mechanical and chemical 
mechanisms. In situations of protracted low dose exposure these protective mechansims 
can be overridden. Proteins of the choroid plexus and the MT protein protect the CSF 
compartment from metal neurotoxicants. 
 
 
3.4.5.1 Barriers 
In the study of this thesis concentrations of 9 metals were found statistically 
significantly elevated in ALS CSF compared to controls. When the metals theoretically 
predicted (Zheng 2001) to accumulate in CP or CSF are compared to the metals 
measured and found in ALS CSF in this study a congruence can be noted (Table 6). 
 
Table 6. Metals known to accumulate in the choroid plexus compared to metals 
detected in ALS CSF1. 
Accumulating  Hg Cd As Pb Mn Cu Fe Ag Zn Al # # # 
Detected    Cd   Pb Mn Cu     Zn Al Co V U 
Match  Χ  Χ Χ Χ   Χ Χ    
 
1
Different shades of grey indicate three different mechanisms of metal toxicity to the 
choroid plexus :(a) █ General choroid plexus toxicants. (b) █ Selective CP toxicants. 
 (c) █ Barrier stored toxicants (Zheng 2001). Aluminium data from (Reusche et al. 
2001). Metals with unknown CP accumulation properties are marked with #. 
 
 
The metals Cd, Pb, Mn, Cu, Zn and Al, known to accumulate in the CP, are found in 
elevated concentrations in the CSF of ALS patients, but not Hg, As, Fe and Ag. For the 
detected metals Co, V and U their fate in the CP is yet unknown. It can be noted that 
Hg and As, both described as general CP toxicants, not were significantly elevated in 
our study, however they were elevated in ALS CSF, as they were in some controls. 
 
In order to reach anterior horn cells of the spinal cord these metals have to enter the 
systemic circulation via various entry routes (see 2.1) penetrating external protective 
barriers such as the alveolar and capillary endothelium of the lung, the intestinal 
mucosa of the gut, the squamous dermal cell layers of the skin or the axoplasmal 
membrane of peripheral nerve cells. Once present in systemic circulation metals are 
still outside of the nervous system, well protected by the BBB, separating brain 
capillaries from the interstitial fluid of brain nerve cells, and the BCSFB, separating the 
systemic circulation from the CSF compartment. 
 
Ultrafiltration of blood produces CSF in the CP and metals that cross the CP from 
blood enter the CSF (Zheng et al. 2003). However some metals are sequestered in the 
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CP (Zheng et al. 1991)  yet other metals may cause morphological damage to the 
membrane epithelial tight junctions of the CP itself (Valois and Webster 1989, Zheng 
2001). 
 
Specifically accumulation of metals in the CP structures and in the CSF has been 
described on theoretical grounds for these metals based on the mechanisms of their 
actions (Zheng 2001). Metals acting on the CP
i
 are by Zheng classified as: (a) General 
choroid plexus toxicants, accumulating in the CP and destroying CP structures, 
including Hg, Cd and As and (b) Selective CP toxicants, acting on critical regulatory 
functions of the CP including Pb, Mn, Cu and Te and (c) Barrier stored toxicants, that 
deposit in the CP however not yet assigned pathophysiological consequences, including 
Fe, Ag, Zn and Au. 
 
Metal transport mechanisms across the barrier systems include both passive diffusion 
and active transporters forming a complex web of transport proteins selective for each 
metal or nonselective but valence dependent. Transport mechanisms have been well 
studied for Mn (Yokel 2009) showing a slow passive efflux of Mn from the brain and a 
carrier-mediated Mn influx to the brain indicating Mn accumulation in the CNS with 
repeated exposure. Aluminium has also been shown to accumulate in the CP but its 
mechanism of action is yet unsettled (Reusche et al. 2001). Metals shown (Zheng 2001) 
to accumulate, at different rates and by various mechanisms, in the BBB and BCSFB 
are Hg, Cd, As, Pb, Mn, Cu, Fe, Au and Zn. 
 
 
3.4.5.2  Metallothionein 
Cadmium and Zn, known to induce MT, were found (Paper VI) in significantly 
elevated concentrations in ALS CSF in our study and the question arises if MT is 
induced in nervous system tissues in ALS as a result of metal exposure. In this section 
the localization of MT in nerve cells is discussed in relation to found metals. 
 
In a study of ALS spinal cord sections immunoreactivity towards MT was found in the 
anterior horn confined to the nucleus, cytoplasm and cytoplasmatic extensions of 
astrocytes. No staining was observed in neurons (Sillevis Smitt et al. 1992). 
Statistically significantly elevated MT concentrations were found in liver (p<0.002) and 
kidney (p<0.003) from ALS patients compared to controls. Serum MT levels from the 
same patients were not elevated (Sillevis Smitt et al. 1994). 
 
Some studies have also addressed the precise localization of MT in ALS spinal cords. 
From experiments with Hg-exposed mice with (wild type) and without (MT 1+2 
double knockout mice) MT it was concluded that in the spinal cord MT was expressed 
in all white matter astrocytes and in some grey matter astrocytes but notably motor 
neurons did not express MT. The presence of MT could not be demonstrated in the 
axons of the ventral roots of neurons (Stankovic et al. 2003). Other experiments have 
demonstrated significantly (p<0.0032) reduced mean axon diameter in MT double 
                                               
i In animal experiments producing these data metal concentrations higher than anticipated in human 
exposure situations have been used.  
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knockout mice after Hg exposure (Stankovic 2005). Reduced axon diameter 
corresponds to muscle atrophy in a proportional manner. 
 
Motor neurons of the anterior horn seem to lack protection from MT. The notion of 
reduced MT protection in ALS spinal cord neurons is further supported by a 
immunohistochemical study of ALS spinal cords (Hozumi et al. 2008) where the 
immunoreactivity of MT1+2, and to some extent MT3, was reduced in grey matter of 
the cord in ALS patients compared to controls. The more severe cases presented the 
deeper reduction in MT immunoreactivity. 
 
Other studies (Blaauwgeers et al. 1993, Suzuki et al. 1994)  have shown that MT1 and 
MT2 are selectively localized to astrocytes. One in vitro study (Hidalgo et al. 1994) 
shows some tenfold higher MT-I level in astrocytes compared to neurons. The 
neuroprotective role of astrocyte MTs could be mediated via sequestering neurotoxic 
metals from the extracellular space surrounding neurons or by routing metals between 
neurons and astrocytes or by acting as a sink for toxic metals such as Cd and Hg by 
keeping them in their non-toxic form bonded to sulphur within the MT sulphydryl 
groups (Aschner 1997). 
 
Binding of metal neurotoxicants to astrocytes from the intracellular space surrounding 
ALS anterior horn neurons may constitute a protective mechanism in situations of 
elevated metal load. If saturated this mechanism leaves the neurons vulnerable, void of 
protection from the metal binding capacities of MTs. A selective vulnerability of 
neurons in the anterior horn of the spinal cord is in accordance with many findings in 
ALS metal interactions. 
 
 
3.4.6 Selective vulnerability of anterior horn cells 
Murine spinal cord anterior horn neurons do not express MT (Stankovic et al. 2003). 
From several rodent Hg exposure experiments (2.2.2), and primate Hg inhalation 
experiments (Paper III), and from ALS data on MT (4.7) it can be concluded that 
anterior horn neurons of the spinal cord are selectively affected by metals with 
neurotoxic properties. The surrounding astrocytes seem to be spared in several different 
studies. Metallothionein, providing protection to metal toxicity, is found in astrocytes 
but not in neurons of the spinal cord anterior horn. The reason for this selective 
vulnerability remains unknown but may have evolutionary causes as the same picture is 
noted in several species. Metallothioneins are highly stable throughout the phylogenetic 
tree (Capasso et al. 2003) and early adopted mechanisms for metal protection against 
harsh environment for early organisms may have been conserved. 
 
 
3.4.7 Temporal aspects 
Some metal intoxications show a specific temporal behavior. Long time low dose 
exposure increase metal concentrations in tissue and body fluids slowly and no 
symptoms appear during this latency period that may be several years or decades. 
When a critical level of metal has been accumulated and engulfed in the perikarya of 
the affected nerve cells, insidious onset of symptoms may be noted. From that point a 
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slow but steady progress is to be expected as further metal is accumulated. The length 
of this symptom free delay, between onset of exposure and onset of symptoms, is 
dependent on many factors such as concentration of metal, route of exposure, protein 
binding, permeability of protecting barriers and affinity of the nuclear components of 
the nerve cell to the specific metal. 
 
Delayed responses to acute metal intoxications are also described. This latency period 
varies between metal species. It has been best described for methylmercury (Weiss et 
al. 2002)  and determined to 150 days after a one-day exposure,  and for low dose 
chronic methylmercury exposure to be several years. A confirmed case of dermal 
exposure to dimethylmercury (Nierenberg et al. 1998) showed a delay of 154 days 
before onset of neurologic symptoms. The mechanisms of these metal intoxication 
latency periods are discussed in detail for both acute and chronic exposures in (Weiss et 
al. 2002) . Some indications exist that early life exposure to As may cause neurotoxicity 
later in life (Vahter 2008). Latency periods of several decades have been described for 
Hg  in monkeys (Rice 1996). A delayed neurotoxicity of Al has been reported to 
produce muscle weakness (Bugiani et al. 1985). 
 
These historical observations on latency periods between exposure and symptom onset 
in confirmed cases of metal intoxications should be compared to latency periods of 
several years, and in some instances decades between occupational exposure to metals 
(1.4.2) and onset of weakness and atrophy in ALS. 
 
Fetal exposure produces long latency periods in a disorder manifesting itself on average 
in the fifth decade. Maternal metal concentrations may be of interest in evaluations of 
which individuals later in life will be vulnerable to toxic effects of metals. Lifetime 
accumulations may start early. Studies of Hg in adult human spinal cord from 
unexposed individuals have shown presence of Hg in motor neurons both in ALS cases 
and in controls, however no Hg has been found in infant spinal cord (Pamphlett and 
Waley 1998). Yet measurements of early life concentrations of metals with neurotoxic 
properties using modern methods (Harari et al. 2012) may be indicated in long term 
ALS studies. 
 
 
3.4.8 Clincal correlates to toxic effects of metals 
Fasciculations: This symptom from the nervous system, first described as “ muscular 
vibrations-little rapid twitching movements of the individual fasciculi, spreading in 
swift undulations beneath the skin, but not causing a contraction of the entire muscle 
nor any motion of the limb” (Roberts 1858), is observed in ALS patients. 
Fasciculations can be detected with EMG and are sometimes noted months or years 
before the onset of ALS symptoms noticeable to the patient. Fasciculations can be 
registered in ALS together with fibrillation potentials, as a sign of denervation, or as an 
isolated phenomenon (Rosenfeld 2000). Fasciculations have been described in humans 
after exposure to Pb (Seppalainen and Hernberg 1972), As (Heyman et al. 1956, Oh 
1991) , Hg (Adams et al. 1983), Al (Tanndag 1995), Mn (Bleich et al. 2000) and other 
metals. 
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Atrophy: Muscle wasting is the most prominent finding in ALS. The atrophy is slow, 
painless and it has a myotomal distribution. Muscle atrophy in experimental animals or 
human beings has been observed after exposure to Al (Shaw and Petrik 2009, 
Wakayama et al. 1996) , Mn (Couper 1837, Kilburn 1987) , Co (Tower 2010, Vassallo 
et al. 2009) , Cd (ATSDR 2012, Imai and Harada 1995) , Pb (Planches 1839, Tandon et 
al. 2001)  and U (Pasternak 2010). 
 
 
3.4.9 Conjugal ALS 
Two unrelated individuals living together for a long time under the same roof 
developing ALS within the same time span or shortly after each other provide a strong 
argument for en environmental cause of the disorder. Spouses often engage in the same 
daily activities or work, drink the same water and eat the same food often from local 
sources. Several reports of such conjugal ALS exist and describe variations on this 
theme. Thus a shepherd couple from rural regions of Italy developed ALS shortly after 
each other (Poloni et al. 1997) and environmental influence such as pesticide toxicity 
was suspected. An analysis of the common drinking water well revealed no elevated 
metal concentrations. Two conjugal cases are described from southern France, a rural 
region with agricultural traditions (Camu et al. 1994). Another clustering of 9 couples 
in south-eastern France have been described (Corcia et al. 2003) and  2 couples in 
Brazil (Godeiro Jr et al. 2009) and a recent report of one occurrence in Texas (Dewitt et 
al. 2012) of conjugal ALS can be found. Altogether about 20 pairs of conjugal ALS 
have been published (Dewitt et al. 2012). The statistical support for conjugal ALS 
appearing by chance has been discussed (Rachele et al. 1998). The value of conjugal 
cases for an understanding of the environmental influence of metals has also been 
emphasized (Chio et al. 2001). Clusters of conjugal ALS have been described from 
many different regions and countries and local environmental factors, such as metal 
exposure, can be suspected. The nature of such exposure may be complex and varied 
and differ from region to region, calling for thorough chemical investigations of the 
local environment when couples encounter ALS within the same time frame. 
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3.4.10 Suggested model of ALS pathogenesis 
Considering these compilated data from the literature of environmental medicine, 
clinical neurophysiology and neurology, medical geology and inorganic chemistry, 
together with our findings of several neurotoxic metals in ALS CSF the following 
series of events leading to widespread weakness, fasciculations and muscle atrophy are 
suggested: 
 
 Exposure. A very varied and complex long-time low dose exposure to several 
neurotoxic metals, by any of the exposure routes discussed in detail in 2.1, or 
combinations of them. 
 
 Dissemination. An uneven distribution by the bloodstream to various organs 
including the spinal cord and brain. Active inward transport of metals with 
neurotoxic properties into the CSF compartment over the choroid plexus 
barriers acting as a lock. Accumulations of metals in spinal cord and brain. 
 
 Selective vulnerability. Anterior horn cells of the spinal cord less resistant to 
metal toxicity as protective MT is present in astrocytes but not in neurons. 
Neurotoxic metals within the nervous system affect selectively the unprotected 
anterior horn cells of the spinal cord. 
 
 Delayed degeneration of nerve cells by direct metal toxicity, including 
synergistic effects. Slowly degenerating anterior horn cells produce muscle 
weakness and atrophy in a myotomal distribution. 
 
This model, akin to the ADME principle for generalized toxicity (Exley et al. 1996)  
can be applied to humans and animals alike and the existence of EqALS is an argument 
in favour of a metal toxicokinetic model for ALS pathogenesis. Hyperendemic areas of 
combined neurodegenerative disorders including ALS in regions with altered metal 
geology further support this view, as do the presentations of conjugal ALS. 
Occupational exposure to metals preceding symptoms in many cases of ALS, and the 
expected delayed neurotoxicity of certain metals also contribute to an environmental 
understanding of ALS pathogenesis. 
 
The rate of global increase in ALS incidence parallels the increase in environmental 
metal pollution and is not compatible with genetic drift alone as an explanation for this 
increase. The genetic influences on sporadic ALS can be described as weak. 
 
Multi-metal toxicity towards nerve cells modulated by genetically polymorphous 
metalloproteins, most important MT, provide best fit towards existing literature data  
and the results of the study of this thesis presenting elevated ALS CSF concentrations 
of several metal neurotoxicants. 
54 
 
3.4.11 Relevance to other neurodegenerative disorders 
Metal concentrations may be of interest also in the evaluation of other disorders of the 
nervous system. An influence of metals may be suspected in AD, PD, MS, SLE and 
other conditions involving neurodegeneration. Overlap situations between ALS, AD 
and PD exist and common causes for these disorders can be suspected (Eisen and Calne 
1992, Greenfield and Vaux 2002). Findings (Roos et al. 2013) of elevated 
concentrations of metals with neurotoxic properties in CSF from ALS patients lend 
some support to the idea of metals as offending agents in all three disorders, when put 
in context of metal data in relation to PD (Uversky et al. 2001) (Bourassa and Miller 
2012) and AD (Gerhardsson et al. 2008, Nordberg et al. 2007b). Correlations to metal 
findings in these neurodegenerative disorders are given here (Table 7). 
 
Table 7. Some metal observations in neurodegenerative disorders1 
Population Study 
 
Observations Metal Reference 
AD (n=24) 
Controls 
(n=28) 
C/C Plasma levels of Al, Cd, Hg and 
Se increased and Fe and Mn 
lower in AD compared to 
control subjects. 
Al, Cd, 
Hg, Se 
Basun 1991 
AD (n=173) 
Diseased 
Controls 
(n=87) 
Controls 
(n=54) 
C/C Higher plasma concentrations of 
Mn and Hg in AD patients. Not 
elevated CSF Mn and Hg. 
Lower V, Mn, Rb, An, Cs and Pb 
concentration in AD CSF. 
Mn 
Hg 
Gerhardsson  
2008 
AD (n=81) Case Faster decline in higher function 
after one year in patients with 
higher serum Cu levels.   
Cu Squitti 2009 
AD 
 
Controls 
(n=50) 
Rev Copper exposure associated with 
AD 
Cu Brewer 2012 
PD (n=3) 
Controls 
(n=3) 
 
C/C High concentrations of Fe and 
Al in substantia nigra neurons in 
PD. 
Fe,Al Good 1992 
 
PD Rev Metals associated with PD. 
Long time occupational 
exposure to specific metals 
appears to be risk factors for PD.  
Mn,Hg  
Fe,Cu, 
Pb, Al, 
Zn 
Gorell 1999 
PD Rev Manganese associated 
neurotoxicity spares dopamine 
system distinguishing 
manganism from PD. 
Mn Racette 
2012 
MS  Rev Perivenular Fe depositions and 
excess Fe in multiple deep grey 
matter structures.  
Fe Williams 
2012 
SLE C/C SLE cluster found in community 
with elevated ambient air Hg 
concentrations.  
Hg Dahlgren 
2007 
 
 
1 C/C-Case control study, Case-Cases are their own controls, Rev-Review 
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Alzheimer´s disease presented higher plasma concentrations of Mn and Hg than 
controls in a clinical study (Gerhardsson et al. 2008) (Table 7). Simultaneously drawn 
CSF samples did not show elevated concentrations of Mn and Hg but lower 
concentrations of  V, Mn, Rb, An, Cs and Pb compared to controls. It was concluded 
that no consistent metal pattern could be observed in plasma or CSF besides raised 
plasma Hg concentrations. Elevated Hg concentrations in AD have been described 
from several studies (summarized in (Gerhardsson et al. 2008) ), however in CSF no 
elevated Hg concentrations have so far been reported. Some authors describe elevated 
Al and Cu concentrations in CSF from patients with AD. CSF Mn concentrations in 
controls may also be of interest and our finding (Roos et al. 2012b) of Mn median value 
2.08 μg/L (range 0.58-5.40) should be compared to the median CSF Mn concentration 
of 0.73 μg/L (range 0.41-2.0) found in the AD study (Gerhardsson et al. 2008). 
Geographical variations in the populations under study may explain this discrepancy, as 
well as different sampling routines, controls selection or analytical parameters although 
the same analytical method, ICP-MS, was used. 
 
Metal concentration CSF/plasma ratios were calculated in a study (Gerhardsson et al. 
2011) of 264 AD patients and 54 healthy controls to evaluate leakage through the 
BCSFB for certain metals. Significantly lower ratios were found for Mn, Rb, Sb, Pb 
and Hg compared to controls and significantly higher for Co. A subgroup with more 
severe AD showed the same pattern. An increased leakage of those metals with 
increased duration or severity of AD was not observed. A considerable variation in 
permeability of the BCSFB for the different measured metals was noted between 
metals. 
 
CSF concentrations of several metals were studied in 26 AD patients and compared to 
concentrations in 13 controls. Higher concentrations of Cr (p˂0.000026) and Mn 
(p˂0.0046) were found. Also elevated CSF Al concentrations were found in AD 
women when compared to AD men (p˂0.0008) (Johansson et al. 2004) . In a study of 
21 AD patients and 11 controls no correlation between CSF concentrations of Cu, Zu, 
Fe and CSF concentrations of Aβ was found (Nordberg et al. 2007b). 
 
ALS shares some features with PD and AD, such as onset in advanced age, 
degeneration of neurons and occurrence of dementia. In AD phosphorylated tau and 
Aβ accumulates in the brain. Interestingly these very same proteins have been found 
in skeletal muscle in patients with inclusion body myosits (IBM), affecting muscles in 
a widespread distribution. A common pathogenetic mechanism for the brain disorder 
AD and the muscle disorder IMB can be suspected from observations of Aβ 
deposition and phosphorylated tau protein occurrence in both disorders (Murphy and 
Golde 2006) . The binding geometry of metal ions to the amyloid-beta-peptide leads 
to different modified self-assembly patterns profoundly affecting toxicity of these 
peptides (Dong et al. 2007). Long time low-level metal exposure and accumulation in 
muscle tissue and nerve tissue might contribute to these varying toxic effects 
especially in susceptible individuals (Roos et al. 2011). 
 
Parkinson´s disease has been associated with elevated tissue concentrations primarily 
of Mn and Fe and occupational exposure to these metals as a cause of PD have been 
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suggested (Gorell et al. 1999) (Table 7). Elevated Al levels have been detected in 
substantia nigra of PD patients in several studies (Good et al. 1992). Metals, e.g. Cu, 
have also been susptected (Binolfi et al. 2008)  to trigger synuclein aggregation, 
thought to precede PD neuronal degeneration. 
 
Multiple Sclerosis is mainly a demyelinating disorder of the CNS and perivenular 
plaques of demyelination are seen in the brain of MS patients. Several studies have 
identified Fe depositions along blood vessels in MS and Fe accumulations have been 
found in several brain regions (Williams et al. 2012) (Table 7) in patients with MS. 
 
Systemic lupus erythematosus presents with manifestations from the central or 
peripheral nervous system in about half of the cases. The condition involves 
haematological and immunochemical abnormalities affecting several organ systems 
including the lung. Phrenic axonal degeneration causing  paralysis of the diaphragm 
and respiratory arrest  has been described  (Omdal et al. 2004) . The cause of SLE 
nervous system manifestations is unknown, as is the cause of ALS, and some 
similarities between these two multisystem disorders exist. Exposure to petroleum and 
Hg has been shown to correlate to SLE occurrence (Dahlgren et al. 2007) (Table 7). 
Serum Cu levels were elevated compared to controls in a small study on SLE (Yilmaz 
et al. 2005). CSF metal studies in SLE may be indicated. 
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CONCLUSIONS 
 
 ALS patients carrying the H46R mutation show a protracted disease course and 
characteristic phenotype with preserved arm strength (Paper I). 
 
 T-cell cytokine concentrations are not elevated in CSF from patients with ALS 
(Paper II). 
 
 Inhaled Hg vapour reaches the spinal cord of primates (Paper III). 
 
 Combined size exclusion chromatography–high pressure liquid chromatography 
and high resolution–inductively coupled plasma–mass spectrometry are 
sensitive and useful methods for determination of fractionated and total metal 
concentrations in CSF. The techniques are particularly useful for multielement 
analysis of small samples of biological material with low concentrations of 
metals (Paper IV). 
 
 Manganese concentrations are statistically significantly higher in CSF from 
patients with ALS than in CSF from controls (Paper V). 
 
 Manganese concentrations in CSF from patients with ALS are higher than 
blood plasma Mn concentrations indicating transport of Mn into the central 
nervous system across barriers (Paper V).  
 
 In patients with ALS CSF concentrations of the metals Mn, Al, Cd, Co, Cu, Zn, 
Pb, V and U are statistically significantly elevated compared to controls (Paper 
VI). 
 
 Neurotoxic metals, which we all are exposed to from the earliest stages of life, 
can reach and affect the anterior horn cells of motor neurons and thereby 
contribute to the pathogenesis of ALS. 
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4 FUTURE PERSPECTIVES 
 
Study design 
 From the investigations performed in ALS patients as described in this thesis it 
can be concluded that concentrations of certaion metals are elevated in ALS 
CSF compared to controls. Together with literature data a model for ALS 
pathogenesis involving metal toxicity is suggested. To what extent metal 
exposure and toxicity also represents the causal mechanism leading to anterior 
horn cell degeneration in ALS remains to be verified. The study presented 
needs to be repeated in larger cohorts and metal concentrations reinvestigated 
using the same methods or more sensitive future methods. 
 
 In iterating these studies cleanliness and purity are first priority. The sensitivity 
of the HR-ICP-MS method is now within nanomolar range and the limiting step 
in producing reliable data from low concentrations of metal is no longer the 
sensitivity of the instrument but rather the purity of the sampling procedure. 
Performing spinal tap in air-filtered rooms with the patient in direct conjunction 
to the analysis instrument could circumvent some of these difficulties. 
 
Method 
 Electrophysiologcal methods are necessary for proper diagnosis of ALS. Future 
developments include expansion of fast and reliable methods for motor unit 
number estimates such as MUNIX (Nandedkar et al. 2011) suitable for 
monitoring degeneration of axons in ALS and degree of reinnervation in 
conjunction with treatment trials. 
 
 Localization of metals at subcellular levels in neurons and astrocytes can 
produce detailed information about mechanisms of toxicity. Recent 
improvements in multielemental imaging (Bourassa and Miller 2012) provide 
high resolution identification of metals in cells and tissues and can be used to 
forward an understanding of the role of metals in neurodegenerative disorders.  
A systematic search for metals or metal oxides at the nano size scale in ALS 
CSF using electromicroscopic techniques is also of high priority. 
 
 In this study we have discarded the first millilitre of CSF to check for 
punctuation bleeding. Maybe in a future iterated study it would be of interest to 
focus on this first millilitre (Zachau et al. 2012)  and measure metal 
concentrations in that first ml. Filtering  CSF for particle size fractions is 
another possible future option. 
 
 Animal exposure experiments have provided many clues to ALS pathogenesis. 
Future animal studies should focus not only on one single metal but on 
exposure to low dose mixtures of metals with known neurotoxicity as close as 
possible mimicking real life human exposure situations. Further tissue and body 
fluid metal studies of wildlife animals showing motor symptoms are also 
warranted. 
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Clinical 
 Each patient has a unique metal exposure history, varied and complex, 
sometimes irrelevant to the state of disease presented, but often presenting clues 
to pathogenesis. To measure lifetime individual exposure to various metals is a 
complicated task and collaboration between specialists in toxicology, inorganic 
chemistry, environmental medicine, neurology and epidemiology is needed. 
The medical aspects of geology are also important in such an evaluation. Future 
medical exposure teams composed by specialists in these fields of expertise 
may contribute to the understanding of each case of ALS. Cross-disciplinary 
university hospital departments may be needed to meet the expected increase in 
neurodegenerative disorders, including ALS. For the individual patient support 
from such a team focusing on exposure history and sharing knowledge about 
the consequences of various metal exposures would be valuable. 
 
 Earlier studies on ALS causation have suggested a connection between bone 
fractures and onset of the disease (Campbell et al. 1970, Kondo and Tsubaki 
1981, Kurtzke and Beebe 1980). Although the statistics in these studies are not 
totally convincing the idea that bone fractures may lead to nerve cell 
degeneration has appeared in the literature throughout the years and many 
theories, including changes in bone calcium metabolism (Provinciali and 
Giovagnoli 1990) have emerged concerning the possible mechanisms for such 
degeneration. When evaluated in the context of our findings of several metals  
in CSF from patients with ALS, one possible re-interpretation of these older 
studies may be that these ALS patients suffered exposure to metal from the 
osteosynthesis material introduced in the bone fracture repair procedure. 
Titanium intramedullary nails leach several different metal ions into the 
bloodstream and tissues (Woodman et al. 1984) and metal can reach anterior 
horn cells of the spinal cord penetrating protective barriers. The material in 
intramedullary nails, plates, bolts, pins and cerclage has varied over the years 
but electrolytic degradation and possible grinding effects releasing metal into 
the systemic circulation applies to all metal species present in prosthetic and 
osteosynthesis material (Barry et al. 2012, Beaver and Fehring 2012). Further 
studies are needed. 
 
 The possible neuroprotective effects of Mg should be further examined. Low 
environmental Mg concentrations have been shown in regions of ALS 
clustering. Rodents fed low Mg develop motor deficits (Oyanagi et al. 2006).    
 
 Similarities between ALS and other neurodegenerative disorders are of interest. 
In particular similarities to AD, PD and MS. Overlap situations exist between 
all these degenerative disorders and CSF metal concentrations can be measured 
and exposure situations evaluated in overlap cases to investigate the hypothesis 
that these entities are part of a common metal toxicity pattern. 
 
 Metal content of cell fractions, such as platelet mitochondria (Shrivastava et al. 
2011) may unveil yet unknown ultrastructural features of ALS pathology.   
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 The methods of body fluid and tissue sampling and analysis of metals described 
in this thesis can be used in future studies of other degenerative disorders where 
a component of metal toxicity can be suspected. Indications for such 
investigations exist for systemic lupus erythematosos, Parkinson’s disease, 
Alzheimers dementia, multiple sclerosis, autism, myasthenia gravis and 
diabetes mellitus. 
 
 
Global 
 Clues to sources of environmental metal exposure can be found within the 
growing discipline of medical geology (Selinus 2005) .Considerable experience 
is gathered within the geological community and large geochemical databases 
constructed collecting metal geodata from all aspects of the planet. By 
comparing such data to ALS prevalence data and known disease clusters, 
information can be gained about possible causal connections. Especially when 
geosampling (Astrom 2000)  is combined with biosampling using modern 
methods of metal analysis valid comparisons of metal patterns and sources can 
be made. 
 
 In agreement with the conclusions of this thesis that neurotoxic metals seem to 
contribute to ALS no treatment suggestions are given. Metal binding agents 
may be tried but have not proven effective, and side effects prevail. Prevention 
and treatment is provided by removing the source of exposure. In a future 
perspective prevention of the neurotoxicity of metals is urgently needed and all 
aspects of human noxious metal exposure need to be evaluated and alleviated as 
stated in the declaration of Brescia (Landrigan et al. 2007). 
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6 SVENSK SAMMANFATTNING 
 
Amyotrofisk lateral skleros (ALS) är en långsamt framskridande sjukdom i 
nervsystemet som leder till svaghet och muskelförtvining och så småningom 
förlamning av andningsmuskulaturen. Nervceller i ryggmärgen dör vid ALS och 
muskelsvagheten startar i de muskler, oftast handmuskler, som styres av de skadade 
ryggmärgcellerna. ALS är alltid dödlig och överlevnadstiden från diagnos är oftast 2-4 
år, med stora individuella variationer. Sjukdomen har varit känd i mer än hundra år och 
många teorier har presenterats om vad som orsakar ALS. Man har misstänkt virus i 
nervsystemet, störningar i immunsystemet, ärftliga mekanismer, oxidationsskador eller 
inflammationer i nervsystemet och man har misstänkt skador från många olika 
kemikalier. 
 
ALS är en av flera så kallade neurodegenerativa sjukdomar, en sjukdomsgrupp som 
också innefattar Alzheimers demens och Parkinsons sjukdom. Det finns en del likheter 
mellan de här sjukdomarna som gör att gemensamma bakomliggande orsaker till 
neurodegenerativa sjukdomar kan misstänkas. Det finns områden i världen där 
förekomsten av ALS är betydligt högre än normalt, ett faktum som pekar i riktning av 
att någonting i miljön inom dessa områden utlöser eller bidrar till sjukdomen. Det finns 
också områden med flera neurodegenerativa sjukdomar inom samma patient. Hästar 
och andra djur, både i fångenskap och vilda, kan också få ALS. Ytterligare stöd till 
tanken om miljömässiga orsaker till ALS kommer från rapporter om gifta par, som 
lever tätt samman, och som får sjukdomen tätt efter varandra. 
 
Ryggmärgens främre delar, de så kallade framhornen, sänder ut nervtrådar till 
musklerna och det är celler i denna främre del som förtvinar först vid ALS. Runt 
ryggmärgen flyter en vätska som reglerar den kemiska miljön för nervcellerna. Genom 
att ta prov på denna ryggmärgsvätska går det att bilda sig en uppfattning om vad som 
kan skada nervcellerna. Efter studier av den litteratur som finns samlad om ALS har jag 
formulerat hypotesen att metaller kan skada framhorn-cellerna och bidra till att de 
skadas. 
 
Förekomsten av metaller och metallbindande proteiner i ryggmärgsvätska och blodprov 
dels från patienter med ALS och dels från kontrollpersoner som inte har sjukdomen, 
har studerats. Koncentrationer av 22 olika metaller har mätts med modern och mycket 
känslig mätutrustning. Det visade sig att nio av dessa metaller förekom i högre 
koncentrationer hos patienterna än hos kontrollerna. Det var mangan, aluminium, 
kadmium, kobolt, koppar, zink, bly, vanadium och uran som var förhöjda. Flera av 
dessa metaller är kända för att skada nervceller. Det är sannolikt att nervskadande 
metaller bidrar till sjukdomen ALS. 
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